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ABSTRACT 
Devon Karnes Check: Investigating Racial Disparities in Quality of Chemotherapy-Induced Side 
Effect Management Among Medicare Beneficiaries with Early-Stage Breast Cancer 
(Under the direction of Stacie Dusetzina) 
 
If not controlled, chemotherapy-induced nausea and vomiting (CINV) can compromise quality 
of life (QOL) for patients with cancer and may lead to decreased chemotherapy adherence. 
Guidelines therefore recommend that patients receiving highly emetogenic chemotherapy regimens 
prophylactically use potent antiemetics (neurokinin-1 receptor antagonists, or NK1s) to prevent the 
side effect. Racial disparities in NK1 use may contribute to well-documented disparities in breast 
cancer patients’ chemotherapy experience. We had three objectives: (1) Assess racial disparities in 
NK1 use; (2) Assess the role of NK1 use disparities in explaining racial variation in women’s 
treatment experiences (namely, post-chemotherapy healthcare utilization); (3) Assess the impact of 
NK1 formulation changes on disparities over time.  
Using 2006–2012 SEER-Medicare data, we identified a cohort of 1,130 early-stage breast 
cancer patients beginning highly emetogenic chemotherapy. We used Modified Poisson regression to 
assess relationships between 1) patient race and NK1 use, 2) patient race, NK1 use, and CINV-
related healthcare utilization, and 3) chemotherapy initiation year and NK1 use. We examined any 
NK1 use and use of specific NK1 formulations (oral aprepitant and IV fosaprepitant). We present 
adjusted risk ratios (aRR) and 95% confidence intervals (CI). 
Black women in our sample were 32% less likely than white women to use an NK1 (aRR: 
0.68, 95% CI: 0.51-0.91) and 46% less likely to use aprepitant specifically (aRR: 0.54, 95% CI: 0.35-
0.83). There were no disparities in fosaprepitant use. NK1 use disparities did not contribute to an 
increased incidence of CINV-related utilization among black women; risk of outpatient utilization was 
actually lower for black patients at 0.15, compared to 0.23 for white patients. All patients were more 
than twice as likely to use an NK1 in 2011 compared to 2007 (aRR white: 2.67, 95% CI: 2.13-3.35; 
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aRR black: 2.54, 95% CI: 1.03-6.25). However, racial gaps have persisted. In 2011, the likelihood of 
NK1 use was 0.64 for white patients, compared to 0.32 for black patients.  
We observed persistent racial disparities in NK1 use. Disparities may be explained by 
patient-level access barriers or prescribing variation. Future research should assess the underlying 
causes of disparities and the impact of disparities on QOL and chemotherapy schedule adherence.  
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CHAPTER 1. OVERVIEW 
Specific Aims 
Patients beginning cancer treatment have consistently cited chemotherapy-induced nausea 
and vomiting (CINV) as a major and fearful concern.[1] Poorly controlled CINV can have severe 
physiological consequences, including dehydration, nutritional derangements, metabolic imbalances, 
and anorexia.[2] Inadequate CINV control can lead to deterioration of a patient’s functional condition 
and quality of life (QOL). Further, hospital admissions, emergency department (ED) visits, and 
outpatient hospital visits after the first cycle of chemotherapy are both common and costly, with one 
study estimating the cost of treating CINV during the first cycle of chemotherapy at $5,299 among 
patients with a CINV-related visit, and $731 across all patients receiving moderately or highly 
emetogenic chemotherapy.[6] In addition to its implications for QOL and cost, uncontrolled CINV can 
lead to decreased chemotherapy adherence or even withdrawal from beneficial chemotherapy.[2, 7] 
CINV control is therefore a critical aspect of high-quality cancer care and has profound implications 
for patients’ cancer care experience.  
Oncology professional organizations produce and endorse clinical practice guidelines for the 
use of antiemetics to prevent CINV.[8–10] For several years, the guidelines have recommended 
prophylactic use of a neurokinin 1 receptor antagonist (an NK1), the newest and most potent class of 
antiemetic, in combination with other drugs for patients receiving chemotherapy with a high risk of 
CINV. Prior to 2008, aprepitant, an oral drug taken on days 1–3 of the chemotherapy cycle, was the 
only NK1 available. There are access and cost barriers to aprepitant use. First, many patients are 
required to fill a prescription for aprepitant at their home pharmacy. Second, aprepitant is expensive, 
and patients may be subject to high cost-sharing when filling the prescription. Another potential 
barrier is under-prescription of the drug, because providers’ use of antiemetics has been shown to be 
suboptimal.[11–13] Evidence suggests that such barriers may disproportionately affect minority 
patients. Studies of patients with lung, prostate, and colorectal cancers have shown black race to be 
2 
negatively associated with use of antiemetic drugs.[14, 15] Whether this finding extends to NK1s and 
to other cancers is unknown. In addition, although research has demonstrated that black cancer 
patients may be more likely than white patients to have gaps in or to discontinue chemotherapy 
because of hospitalizations and acute illness,[16] possibly due to adverse effects of treatment, no 
study has assessed the role of CINV prophylaxis in explaining these disparities. Finally, analyses of 
recent data are needed to evaluate the impact of the availability of an intravenous NK1 (fosaprepitant) 
on disparities in NK1 use. Because fosaprepitant is administered in the clinic and reimbursed under 
different insurance provisions than oral prescription drugs (i.e., under medical rather than pharmacy 
benefits), its availability may help to obviate access and cost barriers related to use of oral therapy.  
The long-term goal of this line of research is to narrow disparities in the quality of supportive 
cancer care. The objective of this study was to assess the existence and impact of racial disparities in 
prophylactic NK1 use among breast cancer patients, a population who frequently receives highly 
emetogenic chemotherapy. It was my central hypothesis that black women are less likely than white 
women to receive an NK1. Documenting black/white disparities in guideline-recommended CINV 
prophylaxis and whether and how disparities have changed over time is essential for informing 
interventions to address disparities in supportive breast cancer care. To that end, I pursued three 
specific aims using data from the SEER-Medicare linked database.  
Aim 1: Assess the relationship between patient race and prophylactic NK1 use. 
Hypothesis: Black women are less likely than white women to use an NK1.  
Aim 2: Assess the relationship between patient race and CINV-related healthcare 
utilization and, if disparities exist, assess the role of prophylactic NK1 use in explaining them. 
Hypothesis 2a: Black women are more likely to have outpatient visits, emergency department visits, 
and inpatient admissions related to CINV following chemotherapy. Hypothesis 2b: NK1 use 
attenuates racial disparities in healthcare utilization. 
Aim 3: Assess longitudinal trends in use of fosaprepitant and the impact of 
fosaprepitant availability on racial disparities in prophylactic NK1 use. Hypothesis 3a: Use of 
fosaprepitant has increased over time for both racial groups. Hypothesis 3b: Racial disparities in any 
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NK1 use have narrowed due to the introduction of fosaprepitant, which may address cost and access 
barriers disproportionately affecting black patients.  
This study elucidates racial disparities in NK1 use among women with breast cancer (Aim 1) 
and evaluates whether these disparities may help explain disparities in patient outcomes (Aim 2). It 
also assessed whether disparities in NK1 use are changing over time (Aim 3). The results help 
transition current cancer disparities research from focusing primarily on curative treatment to also 
considering supportive care and its implications for patients’ cancer care experience. This work also 
has implications for policy, because it provides needed evidence about the effect of NK1 formulations 
and reimbursement sources on disparities in use.  
Executive Summary 
Patients beginning cancer treatment have consistently cited CINV as a major and fearful 
concern.[1] Poorly controlled CINV can have serious implications for patients’ QOL,[2] healthcare 
services use and costs,[6] and adherence to potentially beneficial chemotherapy.[2, 7] CINV 
prophylaxis is therefore a critical aspect of high-quality cancer care and has profound implications for 
patients’ cancer care experience.  
Oncology professional organizations produce and endorse clinical practice guidelines for the 
use of antiemetics to prevent CINV.[8-10] The guidelines recommended prophylactic use of an NK1 
in combination with other drugs for patients receiving chemotherapy with a high likelihood of CINV. 
Prior to 2008, aprepitant, an oral drug taken on days 1-3 of the chemotherapy cycle was the only NK1 
available. Patients may encounter access and cost barriers to aprepitant use. Many patients are 
required to fill a prescription for aprepitant at their home pharmacy. In addition, aprepitant is 
expensive, and patients may be subject to high cost sharing when filling the prescription. Evidence 
suggests that such barriers may disproportionately affect minority patients. In fact, studies of patients 
with lung, colorectal, and prostate cancer have shown black race to be negatively associated with use 
of other, older antiemetic drugs. [14, 15] Whether this finding extends to NK1s and to other cancers is 
unknown. In addition, no study has assessed the role of disparities in CINV prophylaxis in explaining 
disparate outcomes by race. Finally, analyses of recent data are needed to evaluate the impact of the 
availability of an intravenous NK1 (fosaprepitant) on disparities in NK1 use. Because fosaprepitant is 
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administered in the clinic and reimbursed under different insurance provisions than oral prescription 
drugs, its availability may help to obviate access and cost barriers related to use of oral therapy.  
This study contributes to the cancer disparities literature by assessing the existence and 
impact of racial disparities in prophylactic NK1 use among breast cancer patients, a population that 
frequently receives highly emetogenic chemotherapy. Specifically, this dissertation has three 
objectives, which correspond to three Specific Aims: 1) To assess the relationship between patient 
race and prophylactic NK1 use; 2) To assess the relationship between patient race and CINV-related 
healthcare utilization and, if disparities exist, assess the role of prophylactic NK1 use in explaining 
them; and 3) To assess longitudinal trends in use of fosaprepitant and the impact of fosaprepitant 
availability on racial disparities in prophylactic NK1 use. 
To achieve these objectives, we used modified Poisson regression to assess the 
relationships between: 1) patient race and NK1 use, 2) patient race, NK1 use, and CINV-related 
healthcare utilization following chemotherapy, and 3) chemotherapy initiation year and NK1 use. We 
examined both any NK1 use and use of specific NK1 formulations (oral aprepitant and IV 
fosaprepitant). We present risks and adjusted risk ratios (aRR) with 95% confidence intervals (CI) for 
all outcomes.  
In Aim 1, we found substantial racial disparities in NK1 use. Specifically, we observed that 
black women had a 32% decreased likelihood of using any NK1 for the prevention of CINV (aRR: 
0.68, 95% CI: 0.51-0.91). When examining oral and intravenous NK1 formulations separately, black 
women had a 46% decreased likelihood of receiving oral aprepitant (aRR: 0.54, 95% CI: 0.35-0.83). 
We did not observe a statistically significant racial difference in women’s receipt of IV fosaprepitant 
(aRR: 0.82, 95% CI: 0.51-1.33). The fact that we observed racial disparities in oral but not 
intravenous drug use supports the hypothesis that intravenous fosaprepitant may be more affordable 
and accessible for patients.  
Two explanations for our observation of disparities in aprepitant use are that black women 
are: 1) equally as likely as white women to be prescribed aprepitant but less likely to fill their 
prescriptions, possibly due to financial or other access barriers; or 2) disproportionately likely to see 
providers who do not prescribe NK1s in accordance with clinical guidelines because they are more 
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likely to be treated in lower-performing settings.[15, 17] Both explanations seem plausible given our 
findings. Specifically, the fact that disparities in NK1 and aprepitant use were somewhat attenuated 
when factors related to socioeconomic status (SES) were added to the models suggests that the 
disparities are at least partly explained by SES differences between black and white women. These 
SES differences could translate into differential ability to pay for prescription drugs or differential 
access to high-quality care (including guideline-adherent antiemetic prescribing).[15, 17] Interestingly, 
geographic region also appeared to partly attenuate disparities, suggesting a potential role for 
geographic variation in prescribing in explaining disparities in NK1 use.  
In Aim 2, we observed racial variation in CINV-related healthcare utilization in the 14 days 
following the first chemotherapy infusion. In unadjusted analysis, black women were 37% less likely 
than white women to have healthcare claims related to CINV. Estimates were consistent after 
adjustment for clinical variables but statistically non-significant (aRR: 0.66, 95% CI: 0.42-1.04). The 
racial difference in post-chemotherapy healthcare utilization did not extend to any use of healthcare 
services (aRR: 0.95, 95%CI: 0.89-1.03, p=0.21). NK1 use was positively associated with CINV-
related utilization (aRR: 1.34, 95%CI: 1.07-1.68, p=0.01). This relationship persisted among white but 
not black women.  
The direction of the racial difference in CINV-related utilization that we observed was 
unexpected. Whereas we hypothesized that, possibly due to underuse of NK1s, black women would 
experience more CINV-related utilization following chemotherapy than white women, in our sample, 
black women were actually less likely than white women to have healthcare claims related to CINV. It 
seems unlikely that racial differences in general care-seeking behavior explain this variation, given 
our lack of observation of racial differences in any services use in the 14 days after chemotherapy. 
Therefore, it may be that the variation we observed is specific to CINV or symptom management.  
There are two main reasons black women may be less likely to have claims with diagnosis 
codes related to CINV. First, black and white women may be at equal risk of experiencing CINV but 
black women may be less likely to report this experience to their providers. Differential reporting could 
be the result of several factors. For example, different demographic groups may have differential 
thresholds for reporting symptoms to their providers.[18] Alternatively, others have suggested that 
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minorities may receive suboptimal care due to decreased self-efficacy, defined as patients’ perceived 
ability in obtaining needed information and attention regarding their medical concerns.[19] A second 
potential explanation is that the black women in our sample may differ from white women with respect 
to unmeasured factors (e.g., body mass index), which could affect the incidence of treatment-induced 
side effects like CINV. [18, 20, 21] The positive association between prophylactic NK1 use and CINV-
related utilization that we observed in Aim 2 was also surprising. We suspect that confounding by 
indication may account for this relationship. For example, patients’ (or their providers’) level of 
concern about CINV might help explain why patients who receive NK1s are also more likely to 
subsequently receive care related to the side effect.  
Finally, in Aim 3, we hypothesized that fosaprepitant availability would lead to increased NK1 
use for both black and white patients and that, by providing a more accessible and affordable 
alternative to three-day oral aprepitant, the introduction of fosaprepitant may have helped reduce 
racial disparities in NK1 use. Specifically, we hypothesized that in the post-approval period, providers 
may have prescribed fosaprepitant with increased frequency to patients who may experience cost or 
access barriers to prescription medication use, for example low income or minority patients.[22–24] In 
our sample, any NK1 and fosaprepitant use did in fact increase over time for both white and black 
patients. Patients of both racial groups were more than twice as likely to use an NK1 in 2011 
compared to 2007 (aRR for white patients: 2.67, 95% CI: 2.13-3.35; aRR for black patients: 2.54, 
95% CI: 1.03-6.25). Likewise, both groups experienced large increases in fosaprepitant use between 
2009 and 2011 (aRR for white patients: 2.53, 95% CI: 1.75-3.65; aRR for black patient: 3.26, 95% CI: 
0.67-15.91). However, racial gaps have persisted. In 2007, the likelihood of NK1 use was 0.24 for 
white patients and 0.13 for black patients, increasing to 0.64 and 0.32 for white and black patients, 
respectively, by 2011. That NK1 use has improved for all patients in our sample is encouraging and 
suggests that over time more patients are receiving adequate prevention of CINV. However, the 
persistent racial gap that we observed indicates that the CINV prevention needs of many black 
women are not being met. Thus, targeted efforts to increase NK1 use among black patients may be 
needed.  
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To inform these efforts, future research should assess the contribution of provider versus 
patient-level barriers to use. For example, black women may be more likely to receive care within 
lower-performing systems[17] where providers do not routinely prescribe NK1s in accordance with 
clinical guidelines[15] either because the systems’ antiemetic order sets do not align with guidelines 
or because individual prescribers are unfamiliar with the guidelines.[11] Alternatively, black women 
and white women may be equally likely to be prescribed an NK1 but black women may be less likely 
to fill a prescription for aprepitant due to financial[22] or other access barriers[23, 24]. Strategies that 
facilitate providers’ prescription of IV antiemetics, including fosaprepitant as a substitute for three-day 
oral aprepitant, may improve overall rates of guideline-concordant CINV prophylaxis, particularly for 
patients who have difficulty accessing or adhering to more complex oral regimens.  
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CHAPTER 2. STUDY RATIONALE 
Background  
Racial Disparities in Breast Cancer Treatment and Outcomes  
Racial disparities in breast cancer–specific mortality are well documented.[1] Biological 
differences may partially explain these disparities. Specifically, black women are more likely than 
white women to present with aggressive tumors (e.g., triple negative disease).[2] However, 
differences in tumor biology only partially explain racial disparities in patient outcomes, suggesting 
that access to and quality of care may contribute to these disparities.[1, 3–6] For example, black 
women are less likely to receive guideline-concordant mammographic screening for breast cancer 
prevention, resulting in a disproportionate burden of late-stage or terminal disease in this 
population.[7] Even when controlling for stage at diagnosis, however, black breast cancer patients 
fare worse than their white counterparts, possibly due to differential treatment.[8] Specifically, black 
women are less likely to receive radiation therapy[7] and adjuvant chemotherapy[3, 9] in accordance 
with clinical practice guidelines. Disparities also exist among women who do receive chemotherapy. 
Studies investigating racial and socioeconomic disparities in quality of systemic treatment have 
documented disparities in selection of chemotherapy regimens,[10] selection of chemotherapy doses 
in the initial course of chemotherapy,[11, 12] dose reductions in the course of chemotherapy,[13] 
prolonged time to chemotherapy completion,[14] and termination of chemotherapy before all planned 
cycles.[12]  
Racial Disparities in Supportive Cancer Care 
Racial disparities in breast cancer care are not limited to anti-neoplastic treatment. Several 
studies have documented disparities in supportive care, including symptom management, among 
patients with breast and other cancers. Specifically, racial/ethnic disparities have been demonstrated 
in outcomes related to symptom burden and severity,[15, 16] adequacy of pain treatment,[17–19] and 
patients’ perceived unmet need for supportive services.[20] These disparities persist even as 
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supportive care is becoming recognized as an integral aspect of high-quality cancer care because of 
its implications for patient and caregiver quality of life (QOL). [21, 22] In breast cancer in particular, 
where advances in treatment have improved overall survival,[23] patients’ QOL is an increasingly 
important endpoint of care.[24]  
Racial Disparities in CINV Prevention (Aim 1)  
 Quality of CINV prophylaxis has received relatively little attention in the supportive breast 
cancer care literature, even though breast cancer patients routinely receive chemotherapy regimens 
that have a high risk of causing symptoms.[25] Although no studies have evaluated variation in quality 
of CINV prevention in the breast cancer setting, two have documented disparities in use of 
antiemetics among patients with other cancers. Only one study, conducted by Samuel and 
colleagues, specifically investigated racial disparities in the use of antiemetics for CINV prophylaxis 
as one of 20 cancer care quality indicators. [26] This study focused on patients with colorectal, 
prostate, and lung cancers. Although the study did document racial disparities in antiemetic use, the 
generalizability of the study’s results is limited by its focus on the Veterans Affairs system. As well, 
the study used data from the early 2000s, before NK1s were available and recommended by clinical 
guidelines for the prevention of CINV. Another study conducted by Gomez and colleagues explored 
patterns of guideline-concordant antiemetic use among lung cancer patients.[27] Although the 
analysis was not focused on disparities, the authors did note racial and income disparities in 
antiemetic use. This study was also limited by its use of data from a single state’s cancer registry and 
its lack of prescription drug data. In addition, because NK1 use was quite low in this sample (possibly 
due to the recent availability of aprepitant during the study period), NK1s were excluded from the 
analysis.  
Whether documented disparities in guideline-concordant antiemetic utilization extend to 
breast cancer and NK1s is currently unknown. Research that assesses disparities in guideline-
concordant antiemetic use among breast cancer patients will serve as a first step toward 
understanding the potential role of quality of CINV prophylaxis in contributing to racial disparities in 
breast cancer care and outcomes.  
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Racial Differences in Women’s Treatment Experiences (Aim 2)  
Assessing disparities in CINV control in the breast cancer setting is further justified by the 
existence of known disparities in women’s treatment experiences. Previous research has 
demonstrated that black women are less likely than white women to adhere to guideline-
recommended adjuvant chemotherapy regimens. Namely, they are more likely to experience dose 
reductions in the course of chemotherapy,[13] prolonged time to chemotherapy completion,[14] and 
termination of chemotherapy before all planned cycles.[12] As well, black women are more likely to 
experience delays during or termination of adjuvant chemotherapy due to acute illness, 
hospitalizations, missed appointments, and patient decision.[12] Although others have suggested that 
differential experience with chemotherapy could be due to racial differences in women’s ability to 
afford the sometimes expensive medications needed to prevent and control side effects,[28] the role 
of side effect management in explaining disparities in women’s treatment experience has never been 
empirically evaluated.  
A handful of studies have examined patterns in women’s healthcare utilization while 
undergoing adjuvant chemotherapy for early-stage breast cancer.[29–32] However, none included 
patient race as a covariate. A study by Enright and colleagues did include data on patients’ income 
and found evidence of potential variation by income in patients’ hospitalizations and use of the 
emergency department (ED) during chemotherapy, with lower income patients more likely than high-
income patients to experience these outcomes.[33] Studies that assess racial disparities in side 
effect-related healthcare utilization and the link between quality of CINV prophylaxis and utilization 
will help clarify the potential role of side effect management in contributing to racial disparities in 
breast cancer patients’ treatment experiences.  
Changes in Drug Formulation and the Impact on Disparities in CINV Prevention (Aim 3)  
NK1 formulation has changed over time, but how changes have impacted overall NK1 use 
and disparities in use has yet to be evaluated. Prior to 2008, aprepitant, an oral drug with a 
recommended three-day dosing regimen, was the only NK1 approved for CINV prophylaxis. Access 
and cost barriers to aprepitant use exist. First, in many cases, patients are required to fill a 
prescription for aprepitant at their home pharmacy rather than receive it in the clinic at the time of 
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their chemotherapy infusion. Second, the drug is expensive and patients may be subject to high cost-
sharing, particularly under Medicare Part D. In a discrete choice experiment assessing patients’ 
willingness to pay to prevent CINV, the authors concluded that cost contributed more to patients’ 
choices about avoiding CINV than any other single attribute, suggesting that the cost of medications 
to prevent CINV may affect patients’ likelihood of using of them.[34] In general, previous research 
supports a link between higher monthly medication costs and non-adherence [35, 36] and studies 
have suggested that cost-related barriers to use of and adherence to prescription medications for 
cancer and other conditions may disproportionately affect minority patients.[37–39]  
In 2008, an intravenous, provider-administered formulation of aprepitant (fosaprepitant) was 
approved by the FDA, and in 2010, clinical trials demonstrated that a single-dose fosaprepitant 
infusion could serve as a full replacement for the three-day oral aprepitant regimen.[40, 41] Because 
fosaprepitant is administered once in the clinic, simplifying the dosing regimen and removing the 
requirement for patients to take an NK1 at home, it may decrease the number of patients receiving 
suboptimal CINV control.[42] As well, because it is covered under different insurance provisions, 
fosaprepitant may also be more affordable for patients. Research estimating the impact of 
fosaprepitant availability on overall use and disparities in use of NK1s could have implications for 
policies that drive providers’ prescribing practices. 
Study Rationale 
Significance  
This research advances our understanding of potential racial disparities in prophylactic NK1 
use among Medicare beneficiaries receiving highly emetogenic adjuvant chemotherapy for breast 
cancer. It also assesses whether disparities in use are changing over time in response to the 
availability of alternative drug formulations and reimbursement. This contribution is significant 
because it provides actionable evidence to healthcare providers and policy makers attempting to 
reduce racial disparities in supportive breast cancer care.  
CINV is a common and fearful side effect of chemotherapy that can have severe implications 
in terms of QOL, cost, and treatment adherence. CINV is a persistent problem for patients receiving 
chemotherapy[43] and can adversely impact their QOL.[44–46] CINV-related hospital admissions, ED 
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visits, and outpatient hospital visits are also costly.[47] In addition to its implications for QOL and cost, 
uncontrolled CINV can lead to decreased chemotherapy adherence and even early termination of 
beneficial chemotherapy. 
Guidelines recommend the use of potent antiemetics, called NK1s, for patients receiving 
highly emetogenic chemotherapy. Prior to 2008, aprepitant, an oral drug, was the only NK1 available. 
Several factors may complicate its use. First, in most hospitals and private practices, providers 
cannot dispense aprepitant in clinic. Therefore, patients are usually required to obtain the drug from a 
pharmacy. Aprepitant is also very expensive and, particularly when reimbursed under Medicare Part 
D, patients may be responsible for a large portion of the cost. Evidence suggests that cost and 
access barriers to antiemetic use may disproportionately affect minority patients [26, 27]. 
Understanding the relationship between race and NK1 use among breast cancer patients is important 
because this population frequently receives highly emetogenic chemotherapy. As well, research has 
demonstrated that black breast cancer patients may be more likely than white patients to have gaps 
in or to discontinue chemotherapy because of hospitalizations and acute illness,[12] possibly due to 
adverse effects of treatment. No study has yet assessed the role of CINV control through use of 
antiemetics in explaining these disparities. 
Changes in NK1 formulation and reimbursement may have narrowed disparities in use. In 
2008, the FDA approved the intravenous fosaprepitant for use as a substitution for day 1 of the three-
day oral drug. In 2010, the FDA approved a new dosage of fosaprepitant that would replace all three 
days of the oral drug. Subsequently, clinical guidelines changed to recommend the use of either oral 
aprepitant or single-dose fosaprepitant. Analysis of recent data is needed to evaluate the impact of 
the availability and recommendation for use of fosaprepitant on disparities in use of NK1s. Because 
fosaprepitant is administered in the clinic as a single dose, removing the requirement for patients to 
fill and take the medication prior to and after their chemotherapy infusion, it is expected to decrease 
the number of patients receiving suboptimal CINV control.[41] In addition, because it is covered under 
Medicare Part B, fosaprepitant may also be more affordable for patients. Although Part B tends to 
have 20% co-insurance for all services, most Medicare beneficiaries have supplemental insurance 
coverage to assist with their out-of-pocket Part B costs.[48]  
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This study examines potential racial disparities in high-quality CINV control in ways that have 
important implications for clinical practice and policy. The results of this study will inform future 
research, clinical practice, and policy. Specifically, future research can be undertaken to elucidate the 
source(s) of disparities (cost, access, and under-prescribing) and, thus, potential interventions to 
address them. Identifying a link between NK1 use and CINV-related healthcare utilization is valuable 
in and of itself for informing interventions to improve the cancer care experience and outcomes for all 
patients in the setting of breast and possibly other cancers. Finally, understanding how formulation 
and reimbursement changes have affected NK1 use may inform policies and interventions to facilitate 
prescription and use of IV antiemetics.  
Innovation 
Research on breast cancer disparities has focused predominantly on describing disparities in 
curative treatment, particularly adjuvant systemic treatment. Numerous studies have documented that 
African American women are more likely than white women to underuse adjuvant chemotherapy,[49] 
and that, among patients who do initiate adjuvant chemotherapy, disparities exist in the selection of 
chemotherapy doses in the initial course of chemotherapy,[11, 12] dose reductions in the course of 
chemotherapy,[13] prolonged time to chemotherapy completion,[14] and termination of chemotherapy 
before all planned cycles.[12] Potential disparities in the quality of cancer treatment–induced side 
effect management, however, remain largely unstudied.  
Without a better understanding of patterns and potential disparities in side effect 
management and how changes in the availability and reimbursement of supportive medications have 
impacted these patterns, the field cannot advance toward developing strategies to improve the cancer 
care experience and outcomes of breast and other cancer patients. This research is innovative mainly 
because it represents a substantive departure from the status quo by shifting the focus of breast 
cancer disparities research from describing the existence of disparities in curative treatment to 
investigating potential disparities in side effect management, which may impact patients’ QOL as well 
as the quality of their treatment and outcomes.  
This study assesses the relationship between patient race and the use of recommended 
antiemetics (NK1s) for the prevention of CINV among women receiving highly emetogenic adjuvant 
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chemotherapy for breast cancer. It also assesses the role of NK1 use in explaining potential racial 
disparities in patient outcomes, including ED visits and hospitalizations. Although others have 
speculated that disparities in breast cancer treatment and outcomes may be due, in part, to black 
women’s underuse of prescription medications to control adverse effects of treatment,[28] racial 
disparities in the use of these medications and their impact on outcomes have not been studied. 
Findings from this study can provide an example of new research focused on assessing potential 
disparities in the quality of supportive cancer care and the impact of these disparities on patient 
outcomes.  
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CHAPTER 3. METHODS 
Conceptual Model 
Analyses followed a conceptual model adapted from Andersen’s behavioral model of 
healthcare services use. As described in Figure 1, the model demonstrates how environmental 
factors and population characteristics (including predisposing characteristics, enabling resources, and 
need) influence healthcare utilization behaviors and, ultimately, health outcomes.[1] 
Predisposing Characteristics  
There are several indirect pathways through which patient race may impact utilization of 
NK1s. First, black patients may be less likely than white patients to have access to a home pharmacy 
due to, for example, lack of convenient transportation.[2, 3] Second, they may be less likely to be able 
to afford the copayment for an aprepitant prescription.[4] Third, black patients may have limited 
access to high-quality healthcare facilities, resulting in receipt of lower quality care, including 
suboptimal CINV prophylaxis. Fourth, providers may have biases, including prejudices, clinical 
uncertainty, and stereotypes that impact the quality of care they deliver to minority patients.[5] Race 
may also have an indirect effect on CINV-related healthcare utilization through its effect on antiemetic 
use. If black patients are less likely to use NK1s and therefore more likely to experience uncontrolled 
CINV, they may be at increased risk for CINV-related healthcare utilization.  
Enabling Resources  
Patients’ social support (measured as marital status in this analysis) is an important predictor 
of receipt of and adherence to cancer treatment. Financial resources and socioeconomic status 
(SES) also affect patients’ access to care and their healthcare utilization behavior.[6–8] In this study, 
SES is measured at the census tract level. These measures include median income and proportion of 
adult residents without a high school degree. Our study also accounts for patients’ receipt of drug 
copay assistance through Medicare Part D or dual eligibility for Medicaid, which has been shown to 
improve adherence to prescription medications.[9, 10]  
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Need  
In this study, we controlled for women’s need for health services by controlling for their health 
characteristics, including tumor profile, comorbidities, and age. All women in the study sample have 
the same clinical need, according to guidelines, for prophylactic NK1 use during their first cycle of 
chemotherapy because of their receipt of highly emetogenic regimens. However, other health 
characteristics may influence women’s use of healthcare services in Aim 2.  
Environment 
Previous research suggests that racial disparities in quality of care may be partly explained 
by the healthcare setting because black patients have less access to high-quality provider groups.[11] 
In fact, the recent study by Samuel and colleagues found that racial disparities in use of antiemetics 
were attenuated when hospital fixed effects were included in the analytic model.[12] Because a large 
proportion of cancer patients receive chemotherapy outside of the hospital, the present analysis 
cannot account for hospital effects. However, in sensitivity analyses, we attempted to account for 
variation in prescribing by controlling for provider effects. In our sample, individual providers did not 
treat sufficient numbers of white and black women to successfully conduct such an analysis, thus the 
role of provider-level factors in contributing to disparities in NK1 use remains an important area for 
future research.  
Data  
The data for this study were obtained from the Surveillance, Epidemiology, and End Results 
(SEER)-Medicare linked database.[8] The SEER-Medicare dataset comes from a consortium of 
population-based cancer registries across the United States linked to Medicare claims for health 
services obtained from the time of a person’s Medicare eligibility until death. The SEER data cover 
approximately 25% of the U.S. population with cancer and include characteristics of the incident 
cancer including histology, grade, and stage as well as patient demographic information and vital 
statistics for people living in California, Connecticut, Hawaii, Iowa, Kentucky, Louisiana, New Jersey, 
New Mexico, Utah, rural Georgia, and metropolitan areas of Atlanta, Detroit, and Seattle. The data 
include ecological measures of income, education, and other characteristics drawn from the 2000 
U.S. Census. Fee-for-service Medicare claims (from Medicare Parts A and B) cover hospital services, 
23 
physician services, physician-administered drugs, and other medical services for approximately 70% 
of Medicare beneficiaries.[9] Medicare Part D claims contain information about prescription drugs 
obtained from pharmacies.  
Sample 
We included women aged 65 years and older who were diagnosed with stage I, II, or III 
breast cancer between January 1, 2007, and December 31, 2011. Eligible women were: (1) not 
diagnosed at autopsy or death; (2) continuously enrolled in Medicare Parts A and B for 6 months 
before and 12 months after diagnosis; (3) continuously enrolled in Medicare Part D for 12 months 
after diagnosis; and (4) not enrolled in an HMO for 6 months before and 12 months after diagnosis. 
There were 27,160 women meeting these criteria. From this sample, we restricted our analysis to 
women who received surgery (mastectomy or breast-conserving surgery) and initiated chemotherapy 
within 6 months of diagnosis (n=4,651). The analysis was further restricted to women whose first 
cycle of adjuvant chemotherapy included an anthracycline and cyclophosphamide (n=1,569), 
because guidelines have consistently recommended use of an NK1 for these regimens throughout 
the study period.[10–14] Because of the small proportion of non-black minorities, the study was 
restricted to black and white women (n=1,451). Finally, because Part D claims are available starting 
on January 1, 2007, women in our sample initiated chemotherapy on or after February 1, 2007, so 
that we could observe Part D claims for antiemetics in the 30 days before chemotherapy initiation 
(n=1,130). In Aim 3, the sample was further restricted to women initiated chemotherapy before 
January 1, 2012 (n=1,087), to allow for a year of follow-up. A CONSORT diagram is displayed in 
Figure 2.  
Key Variables  
The main independent variable for Aim 1 was patient race (black or white). In Aim 2, both 
patient race and prophylactic NK1 use were independent variables of interest. In Aim 3, our 
independent variable was chemotherapy initiation year. Patient-level covariates are drawn from the 
SEER-Medicare dataset. Specifically, patients’ socio-demographic and cancer information are 
contained in the Patient Eligibility and Diagnosis Summary File (PEDSF) of the SEER-Medicare data. 
Area-level measures of income and education were drawn from the 2000 U.S. Census. Patients’ 
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comorbidities were measured using data contained in the Medicare Parts A and B claims files and the 
comorbidity index developed by Klabunde and colleagues.[15]  
The dependent variables for all three aims were measured using the Medicare Parts A, B, 
and D claims files. In Aims 1 and 3, among women beginning their first cycle of highly emetogenic 
chemotherapy, we assessed the likelihood of using an NK1 for CINV prophylaxis. NK1 users were 
defined as having a Medicare Part D claim for aprepitant (oral formulation), as identified by the drug 
name, in the 30 days before or on the day of chemotherapy initiation from the Prescription Drug 
Events file. Alternatively, they had a Part B claim for aprepitant in the 30 days before or on the day of 
chemotherapy initiation as identified using Health Care Common Procedure Coding System codes 
(J8501) and as recorded in the outpatient, physician services, or durable medical equipment claims 
files. Finally, NK1 users could have a claim for fosaprepitant (IV formulation) (C9242, J1453) on the 
day of chemotherapy initiation, as recorded in the outpatient or physician services files.  
In Aim 2, the dependent variable was any CINV-related utilization, measured as any 
outpatient or inpatient claims with an associated diagnosis of nausea and vomiting (ICD-9 codes 
787.0-787.02), volume depletion (ICD-9 code 276.5), dehydration (ICD-9 code 276.51), or 
hypovolemia (ICD-9 code 276.52) in the 14 days following chemotherapy administration.[16] The key 
independent and dependent variables and covariates are summarized in Table 1.  
Analytic Approach 
The analytic approach for Aims 1, 2, and 3 are outlined below. Overall, we used two 
approaches to assessing racial disparities. In the primary set of models we implemented the Institute 
of Medicine’s (IOM) definition of a racial healthcare disparity, that is, a difference in treatment not 
justified by differences in clinical characteristics of the racial groups.[2] Analytic approaches to 
implement this definition of disparities use statistical models that control only for differences in health 
status (e.g., co-morbidity, age) and clinical need (e.g., tumor characteristics) and, if available, 
preferences for care between racial groups. This approach recognizes the mediating role of an 
individual’s SES and related factors, because minorities tend to have lower SES profiles than whites, 
and that such differences can impact care received. However, such approaches do not adjust for 
SES-related factors, because doing so may reduce or eliminate the estimated independent effect of 
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race on care and give a false picture of the care experience of vulnerable patients. [7, 17, 18] 
Approaches to implement the IOM definition of disparities may also not adjust for other potential 
mediators of disparities, namely, marital status and geography.[18]  
The second, more traditional approach to assessing disparities is to estimate the residual 
direct effect of race, controlling for all potential mediators of the relationship between race and the 
outcome, including measures of SES, marital status, and geography. Our secondary models for Aims 
1 and 2 used this approach to provide a more conservative estimate of the effect of race on each 
outcome. In Aim 3, we used only the IOM approach to assessing disparities.  
Aim 1: Assess the Relationship Between Patient Race and Prophylactic NK1 Use 
First, we examined the distribution of patient characteristics between racial groups using chi-
squared tests. We then assessed the relationship between race and prophylactic use of 1) any NK1, 
2) aprepitant (oral formulation), and 3) fosaprepitant (IV formulation). To directly estimate risk ratios 
with robust error variance, we used modified Poisson regression models,[19, 20] estimating 
generalized linear models with a Poisson distribution and log link. Because black women are 
disproportionately likely to receive drug copay assistance through Medicaid dual eligibility or a Part D 
low-income subsidy,[21, 22] we included a drug copay assistance indicator and an interaction of race 
and copay assistance in our primary NK1 and aprepitant models to determine whether the models 
should be stratified by drug copay assistance receipt. Because the interaction effect was not 
statistically significant, we present the main effects models in this dissertation. The empirical models 
are shown below. Primary models controlled only for patients’ clinical characteristics while secondary 
models also controlled for SES measures and other potential mediators of disparities, including 
marital status and geography.  
 
Primary model: NK1 use = β0 + β1Race + B2Clinical Covariates + u 
 
Secondary model: NK1 use = β0 + β1Race + B2Clinical Covariates + B3SES + B4OtherMediatiors + u 
 
 
In a sensitivity analysis, we excluded tumor characteristics from the primary NK1 models 
because these factors should not influence a patient’s risk for CINV or need for antiemetics. Further, 
because advanced stage at diagnosis,[23, 24] hormone receptor negative phenotype, and high grade 
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are more common in black women,[23, 25] including these covariates might actually attenuate the 
effect of race on likelihood of receiving CINV prophylaxis.  
Aim 2: Assess the Relationship Between Patient Race and CINV-Related Healthcare Utilization 
We used modified Poisson regression to assess the relationships between: 1) race and 
CINV-related healthcare utilization, and 2) NK1 use and CINV-related utilization overall, stratified by 
race.  
 
Primary model for race and CINV-related utilization: CINV-Related Utilization = β0 + β1Race + 
B2Clinical Covariates + u 
 
Secondary model for race and CINV-related utilization: CINV-Related Utilization = β0 + β1Race + 
B2Clinical Covariates +B3SES + B4OtherMediatiors + u (All) 
 
Models for NK1 use and CINV-related utilization:  
CINV-Related Utilization = β0 + β1NK1 + B2Clinical Covariates + u (All) 
 
CINV-Related Utilization = β0 + β1NK1 + B2Clinical Covariates + u (Black) 
 
CINV-Related Utilization = β0 + β1NK1 + B2Clinical Covariates + u (White) 
 
 
Aim 3: Assess Longitudinal Trends in Use of NK1s and the Impact of Fosaprepitant 
Availability on Racial Disparities in Prophylactic NK1 Use 
We used modified Poisson regression to estimate changes in NK1 use separately by 
chemotherapy initiation year. To determine how changes in NK1 use may differ between racial 
groups, we assessed changes in use of any NK1 and formulation-specific use among black and white 
patients separately between 2007 and 2011. We controlled for select covariates related to patients’ 
health status and tumor characteristics (patient age, comorbidity burden, and cancer stage).  
NK1 use = β0 + B1ChemoYear + β2Race + B3Clinical Covariates + u (Black) 
 
NK1 use = β0 + B1ChemoYear + β2Race + B3Clinical Covariates + u (White) 
 
 
Expected Outcomes 
The expected outcome for Aim 1 was to understand whether racial disparities exist in use of 
NK1s among women receiving highly emetogenic adjuvant chemotherapy regimens. The existence of 
disparities may suggest that black patients are receiving inferior CINV prophylaxis, either because 
their providers are less likely to prescribe appropriate antiemetics or because black patients are less 
likely to fill their prescriptions. Thus, the results of this aim inform future research to elucidate the 
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source of disparities in prophylactic NK1 use and the development of interventions to address these 
disparities. The expected outcome for Aim 2 was to understand the potential impact of disparities in 
NK1 use in terms of patient outcomes. The results of this aim help establish the significance of 
potential disparities in antiemetic use in terms of healthcare utilization and potential cost. They may 
also help inform the design of interventions aimed at reducing avoidable utilization among breast 
cancer patients. The expected outcome of Aim 3 was to understand whether use of fosaprepitant, 
compared to oral aprepitant, has increased over time for both racial groups and to understand 
whether the availability and recommendation of fosaprepitant has helped narrow racial disparities in 
the use of NK1s. These results fulfill Aim 3’s objective of assessing the impact of changes in the 
formulation and reimbursement of NK1s on disparities in their use and may have implications for 
providers’ prescribing practices and for Medicare reimbursement policy.  
Taken together, the results of this study elucidate potential disparities in a critical aspect of 
supportive breast cancer care. In doing so, they will help transition current cancer disparities research 
from focusing primarily on curative treatment to also considering supportive care and its implications 
for patients’ QOL and cancer care experience. 
 
 
 
Figure 1. Adapted Andersen Healthcare Utilization Model for NK1 use. 
28 
 
 
Figure 2. CONSORT diagram showing study inclusion/exclusion criteria. 
  
29 
Table 1. Study Variables for Aims 1, 2, and 3 
Variable Aims Variable Type  Possible values Source 
Key Independent Variables 
Race 1, 2, 3 Binary White/Black Patient Entitlement 
and Diagnosis 
Summary File 
(PEDSF) 
NK1 use 2 Binary Yes/No Medicare claims 
Chemotherapy 
initiation year 
3 Categorical 2007, 2008, 2009, 
2010, 2011, 2012 
PEDSF 
Covariates - Population (Clinical and Demographic) Characteristics  
Age 1, 2, 3 Categorical 65-66; 67-68; 69-71; 
72-92 
PEDSF 
Marital status  1, 2, 3 Binary  Married or 
partnered/Single 
PEDSF 
Drug copay 
assistance 
receipt (through 
Medicaid dual 
eligibility or Part 
D Low-Income 
Subsidy)  
1, 3 Binary Yes/No PEDSF & Part D 
% No HS 
education 
(Census tract)  
1,2,3 Categorical  1.22-9.69%; 9.70-
16.57%; 16.58-
27.88%; 27.89-
75.17% 
PEDSF 
Median income 
(Zip code level) 
1,2,3 Categorical  $0-32,791; $32,972-
44,039; $44,040-
58,436; $58,437-
188,340 
PEDSF 
Metropolitan 
county  
1, 2, 3 Binary Metro/Non-Metro  PEDSF 
Comorbidity 
score 
1, 2, 3 Categorical 0/1/2+ Medicare claims  
Cancer stage  1, 2, 3 Categorical  I/II/III PEDSF 
Lymph node 
involvement 
1, 2, 3 Binary Yes/No PEDSF 
Tumor grade 1, 2, 3 Categorical  Low/Intermediate/High PEDSF 
Hormone 
receptor status 
1, 2, 3 Binary Positive/Negative  PEDSF 
Covariates - Environment  
Chemotherapy 
initiation year 
1,2 Categorical  2007-2012 PEDSF  
US Region 1,2,3 Categorical Northeast/Midwest/W
est/South 
PEDSF 
Dependent Variables 
NK1 use 1, 3 Binary Yes/No Medicare claims  
CINV-related 
utilization  
2 Binary Yes/No Medicare claims  
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CHAPTER 4. INVESTIGATING RACIAL DISPARITIES IN BREAST CANCER PATIENTS’ USE OF 
NK1 RECEPTOR ANTAGONISTS FOR THE PREVENTION OF CHEMOTHERAPY-INDUCED 
NAUSEA AND VOMITING  
Introduction  
 Patients initiating cancer treatment have consistently cited chemotherapy-induced nausea 
and vomiting (CINV) as a major and fearful concern.[1] Poorly-controlled CINV can have severe 
physiological consequences, including dehydration, nutritional derangements, metabolic imbalances, 
and anorexia.[2] Thus, inadequate CINV control can lead to deterioration of a patient’s functional 
condition and quality of life (QOL). [3–5] Further, hospital admissions, emergency department (ED) 
visits, and outpatient hospital visits after the first cycle of chemotherapy are both common and costly, 
with one study estimating the cost of treating CINV between the first and second cycle at $5,299 
among patients with a visit and $731 across all patients receiving moderately or highly emetogenic 
chemotherapy.[6] In addition, uncontrolled CINV can lead to decreased chemotherapy adherence or 
even withdrawal from potentially beneficial chemotherapy.[2, 7] CINV control is therefore a critical 
aspect of high-quality cancer care and has profound implications for patients’ cancer care experience.  
Oncology professional organizations produce and endorse clinical practice guidelines for the 
use of antiemetics to prevent CINV.[8–10] For several years, the guidelines have recommended 
prophylactic use of the most potent class of antiemetic, neurokinin-1 recetpor antagonists (NK1s), for 
patients receiving highly emetogenic chemotherapy. Until 2008, aprepitant, an oral formulation, was 
the only NK1 available for CINV prophylaxis. Barriers to aprepitant use exist. First, in many cases, 
patients are required to fill a prescription for aprepitant at their home pharmacy rather than receive it 
in the clinic at the time of their chemotherapy infusion. Second, the drug is expensive relative to other 
antiemetics and patients may be subject to high cost-sharing, particularly when the drug is filled at a 
pharmacy and reimbursed under Medicare Part D. Estimates suggest that three aprepitant capsules 
cost over $500 under Medicare Part D and patients may be responsible for 25% to 50% of that cost, 
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depending on their phase of the Part D benefit (i.e., in the initial coverage phase or in the doughnut 
hole, respectively).[11]  
Evidence suggests that cost and access barriers may disproportionately affect minority 
patients. Studies of patients with lung, prostate, and colorectal cancers have shown black race to be 
negatively associated with use of other antiemetic drugs.[12, 13] Whether this finding extends to 
NK1s and to other cancers is unknown. Assessing the relationship between race and NK1 use among 
breast cancer patients is particularly important because this population frequently receives highly 
emetogenic chemotherapy. In addition, research has demonstrated that black breast cancer patients 
may be more likely than white patients to have gaps in or discontinue use of chemotherapy because 
of hospitalizations and acute illness,[14] possibly due to adverse effects of treatment. In general, 
minority cancer patients are more likely than white patients to experience uncontrolled symptoms and 
to report inadequate supportive care for pain and psychosocial symptoms.[15–19] As a first step 
toward understanding how the quality of CINV prophylaxis may contribute to racial disparities in 
breast cancer care, we assessed potential racial disparities in prophylactic use of NK1s among early-
stage breast cancer patients beginning a chemotherapy regimen for which use of an NK1 is 
guideline-recommended. We were also interested to learn whether disparities were attenuated by 
intravenous (versus oral) NK1 use.  
Methods  
Data  
We used the National Cancer Institute’s Surveillance Epidemiology and End Result (SEER) 
database linked with Medicare fee-for-service claims from 2006 to 2012. The SEER program consists 
of population-based cancer registries and represents 28% of the population with cancer. SEER data 
are merged with fee-for-service Medicare claims to allow for assessments of health services use 
among Medicare beneficiaries with cancer.[20] Our study was conducted in accordance with a SEER-
Medicare data use agreement and was approved by the Institutional Review Board at the University 
of North Carolina at Chapel Hill. 
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Sample 
We included women aged 65 years and older who were diagnosed with stage I, II, or III 
breast cancer between January 1, 2007, and December 31, 2011 (Figure 1). Eligible women were: (1) 
not diagnosed at autopsy or death; (2) continuously enrolled in Medicare Parts and A and B for 6 
months before and 12 months after diagnosis; (3) continuously enrolled in Medicare Part D for 12 
months after diagnosis; and (4) not enrolled in an HMO for 6 months before and 12 months after 
diagnosis. There were 27,160 women meeting these criteria. From this sample, we restricted our 
study to women who received surgery (mastectomy or breast-conserving surgery) and initiated 
chemotherapy within 6 months of diagnosis (n=4,651). The analysis was further restricted to women 
whose first cycle of adjuvant chemotherapy included an anthracycline and cyclophosphamide 
(n=1,569), because guidelines have consistently recommended use of an NK1 for these regimens 
throughout the study period.[8–10, 21, 22] Our sample was limited to women initiating adjuvant 
chemotherapy following surgery (versus women receiving neoadjuvant chemotherapy) in an effort to 
make the sample as homogenous as possible with regard to treatment experiences and potential 
unmeasured confounders. Because of the small proportion of non-black minorities (n=118), the study 
was restricted to black and white women (n=1,451). Finally, we restricted our sample to women who 
initiated chemotherapy on or after February 1, 2007, so that we could observe Part D prescription 
drug claims for antiemetics in the 30 days before chemotherapy initiation (n=1,130).  
Variables  
 Our primary outcome was patients’ use of an NK1 during the first cycle of adjuvant 
chemotherapy. NK1 users were defined as having a Medicare Part D claim for aprepitant (oral 
formulation), as identified by the drug name, in the 30 days before or on the day of chemotherapy 
initiation. Alternatively, they had a Part B claim for aprepitant in the 30 days before or on the day of 
chemotherapy initiation, as identified using Health Care Common Procedure Coding System codes 
(J8501) and as recorded in the outpatient, physician services, or durable medical equipment claims 
files. Finally, NK1 users could have a claim for fosaprepitant (IV formulation) (C9242, J1453) on the 
day of chemotherapy initiation, as recorded in the outpatient or physician services files.  
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Our main independent variable was race (black or white), as reported in the Patient 
Entitlement and Diagnosis Summary File. Covariates included patients’ demographic and clinical 
characteristics: age, cancer stage, tumor grade, hormone receptor status, lymph node involvement, 
and comorbid illness (calculated using the Klabunde modification of the Charlson score based on 
patients’ Medicare Part A and B claims pre-diagnosis).[23] We also measured marital status and 
receipt of a low-income subsidy to assist with prescription drug costs (i.e., Medicaid dual eligibility 
and/or “extra help” through the Medicare Part D program). Although patients dually eligible for 
Medicare and Medicaid receive subsidies to assist with drug co-pays, their prescription drugs are 
typically covered under Medicare Part D versus Medicaid. Other measures of socioeconomic status 
(SES) included census tract–level high school completion rate and median income, obtained from the 
2000 census. Geographic variables were U.S. region of residence and extent of urbanization at 
patients’ residences.  
Statistical Analysis  
We compared the distributions of patient characteristics between racial groups using chi-
squared tests. To directly estimate relative risk with robust error variance, we used modified Poisson 
regression[24] to assess the relationship between race and NK1 use controlling for pre-specified 
patient characteristics. Because black women are disproportionately likely to receive drug copay 
assistance through Medicaid dual eligibility or a Part D low-income subsidy,[25, 26] we included a 
drug copay assistance indicator and an interaction of race and copay assistance in our primary 
models to determine whether the models should be stratified by drug copay assistance receipt. 
Because the interaction effect was not statistically significant, we present the main effects models. 
Specifically, we present risks and adjusted risk ratios (aRR) with 95% confidence intervals (CI) for 
NK1 use, comparing black and white women. We estimated separate models for any NK1 use, 
aprepitant use, and fosaprepitant use. Because fosaprepitant was not approved by the FDA until 
2008, this model was limited to patients who initiated chemotherapy in 2009 or later (N=524). 
Accounting for Socioeconomic Status. The Institute of Medicine (IOM) defines racial 
healthcare disparities as differences in treatment not justified by racial differences in health status or 
preferences. [27] Analytic approaches to implement this definition of disparities use statistical models 
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that control only for differences in health status (e.g., co-morbidity, age), clinical need (e.g., tumor 
characteristics) and, if available, preferences for care between racial groups.[13, 28, 29] This 
approach recognizes the mediating role of an individual’s SES and SES-related factors, because 
minorities tend to have lower SES profiles than whites and such differences can impact care 
received. Therefore, the IOM’s model does not adjust for SES-related factors because doing so may 
reduce or eliminate the estimated independent effect of race on care and give a false picture of the 
care experience of vulnerable patients. In accordance with the IOM definition of healthcare 
disparities, our primary models adjusted for clinical characteristics, namely: age, year of 
chemotherapy initiation, tumor characteristics, and medical comorbidity.[29] In secondary analyses 
we assessed whether our findings would differ when including census tract–level SES, marital status, 
or geography in the primary model.  
Sensitivity Analyses  
In an exploratory model, we excluded tumor characteristics because these factors should not 
influence a patient’s need for antiemetics. Further, because advanced stage at diagnosis,[30, 31] 
hormone receptor negative phenotype and high grade are more common in black women,[30, 32] 
including these covariates might actually attenuate the effect of race on likelihood of receiving CINV 
prophylaxis. Results from these analyses were consistent with the primary analysis and are not 
shown. 
Results 
Among the 1,130 women who met our eligibility criteria, 1,015 (89.8%) were white. Compared 
to white women, black women were less likely to be married (25% versus 53%) and more likely to 
receive drug copay assistance through Medicaid or Medicare Part D (70% versus 21%). There were 
also racial differences in census tract–level income and education and U.S. region of residence (see 
Table 2).  
 In the unadjusted analyses, we found statistically significant racial differences in women’s use 
of any NK1 (41% white vs. 28% black; p<0.01) and aprepitant use (29% white vs. 16% black, 
p<0.01), but not in fosaprepitant use (15% white vs. 12% black, p=0.41). Unadjusted associations of 
each covariate with NK1, aprepitant, and fosaprepitant use are shown in Table 3.  
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  In models adjusting for clinical characteristics only, racial disparities remained in use of any 
NK1 (aRR: 0.68, 95% CI: 0.51-0.91) and aprepitant (aRR: 0.54, 95% CI: 0.35-0.83). The relationship 
between race and fosaprepitant use was non-significant (aRR: 0.82, 95% CI: 0.51-1.33) (see Table 
4). Secondary models that included measures of SES (census tract–level income and education and 
drug copay assistance receipt), marital status, and geographic factors were consistent with our 
primary models, however estimates were no longer statistically significant. Being black reduced the 
risk of using any NK1 by 19% (aRR: 0.81, 95%CI: 0.60-1.10; NS) and aprepitant by 32% (aRR: 0.66 
95% CI: 0.43-1.104; NS)) (see Table 4).  
Discussion  
 Among women initiating highly emetogenic chemotherapy containing an anthracycline and 
cyclophosphamide for their early-stage breast cancer, we observed that black women had a 32% 
decreased risk of using any NK1 for the prevention of CINV. When examining oral and intravenous 
NK1 formulations separately, black women had a 46% decreased risk of receiving oral aprepitant. We 
did not observe a statistically significant racial difference in women’s receipt of intravenous 
fosaprepitant. When we added SES- and geography-related variables to our models, the relationships 
between race and NK1 use and race and aprepitant, the effect estimates remained consistent with 
disparities but were no longer statistically significant.  
Despite clinical guidelines recommending the use of NK1s for anthracycline- and 
cyclophosphamide-containing breast cancer regimens throughout the study period, only 40% of 
women in our sample used an NK1, according to our definition of prophylactic use. This may be due 
to a lack of provider familiarity with recommendations for NK1s for the chemotherapy regimens we 
examined or institutional policies’ failure to include NK1s in the antiemetic order sets for these 
chemotherapy regimens. Although guidelines have consistently recommended use of an NK1 for 
anthracycline- and cyclophosphamide-containing breast cancer regimens throughout our study 
period, in earlier guidelines, these regimens were classified as “moderately” emetogenic; later in the 
study period, guideline updates reclassified the regimens as “highly” emetogenic.[8–10] This 
explanation is consistent with the substantial increase in NK1 use over time that we observed.  
38 
Our finding of a disparity is consistent with the limited research to date examining variation in 
use of antiemetics for CINV prevention. However, to our knowledge, our study is the first to include 
NK1s. In the only study to date that specifically investigated racial disparities in antiemetic use, 
Samuel et al. focused on patients with colorectal, prostate, and lung cancers in the Veterans Affairs 
system.[13] Although they documented disparities in use of some antiemetics, their data were from 
the early 2000s, before NK1s were recommended by clinical guidelines for the prevention of CINV. 
Gomez and colleagues explored patterns of guideline-concordant antiemetic use among lung cancer 
patients.[12] Although not focused on disparities, the authors demonstrated racial and income 
differences in antiemetic use. However, this study was limited to a single state’s cancer registry and 
did not include NK1s in the analysis. 
 Our study is also the first of which we are aware to examine patterns of use of oral versus 
intravenous NK1s. It is important to distinguish between formulations because many patients are 
required to fill a prescription for oral aprepitant, a high-cost medication, at their home pharmacy. 
Under Medicare Part D, patients may be subject to high cost-sharing. The introduction of intravenous 
fosaprepitant in 2008 may have helped obviate access and cost barriers related to use of oral 
therapy. Specifically, because fosaprepitant is administered in the clinic, it is covered under Medicare 
Part B. Although Part B tends to have 20% co-insurance for all services, a large majority of Medicare 
beneficiaries have supplemental insurance coverage to assist with their out-of-pocket Part B 
costs.[33] Our identification of racial disparities in oral but not intravenous NK1 use supports the 
hypothesis that fosaprepitant is more affordable and accessible for patients. However, it is important 
to acknowledge that the lack of an observed disparity in fosaprepitant use could be due to insufficient 
sample size, because the fosaprepitant models were limited to patients who initiated chemotherapy in 
2009 or later (N=524).  
Two potential explanations for our observation of disparities in aprepitant use are that black 
women are: (1) equally as likely as white women to be prescribed aprepitant but less likely to fill their 
prescriptions, possibly due to financial or other access barriers or (2) disproportionately likely to see 
providers who do not prescribe NK1s in accordance with clinical guidelines because they are more 
likely to be treated in lower-performing settings.[13, 34] Both explanations seem plausible given our 
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findings. Specifically, the fact that disparities in NK1 and aprepitant use were somewhat attenuated 
when SES-related factors were added to the models suggests that the disparities are at least partly 
explained by SES differences between black and white women. These SES differences could 
translate into differential ability to pay for prescription drugs or differential access to high-quality care 
(including guideline-adherent antiemetic prescribing).[13, 34] Interestingly, geographic region also 
appeared to partly attenuate disparities, suggesting a potential role for geographic variation in 
prescribing in explaining disparities in NK1 use.  
Also of note, unlike prior reports, receipt of drug copay assistance appeared to act as an 
indicator of low income rather than as an indicator of increased ability to pay for prescription drugs. 
Specifically, recent work by Neuner and Biggers documented a positive effect of drug copay 
assistance receipt on breast cancer patients’ adherence to aromatase inhibitors.[25, 35] In contrast, 
we observed a negative effect of drug copay assistance receipt on aprepitant use. One possible 
explanation for this difference may be our measure of drug copay assistance receipt, which combined 
assistance through Medicaid dual eligibility and the Part D low-income subsidy (i.e., a woman was 
said to be a drug copay assistance recipient if she received either type of assistance), whereas 
Neuner and Biggers’s studies measured only Part D low-subsidy receipt. Our results may reflect the 
mixed effect of dual eligibility status, which could be an indicator of decreased access, and Part D 
low-income subsidy receipt, which has been demonstrated to improve adherence.  
  Our study had several limitations. First, we focused on fee-for-service Medicare beneficiaries 
with Part D coverage. It is unknown whether our findings generalize to younger women, Medicare 
beneficiaries enrolled in an HMO, or women without prescription drug coverage through Part D. 
Second, in our secondary models, we may have misclassified individuals’ SES by using area-level 
measures of SES.[36, 37] Third, because of the limited number of minority women represented in 
SEER-Medicare, we may have lacked statistical power for some comparisons. This is particularly true 
of the fosaprepitant models, which were limited to the 524 women who initiated chemotherapy in 
2009 or later. Fourth, our use of Medicare administrative claims data for this analysis may have 
resulted in our under-capturing of NK1 use overall if these medications were provided in clinic and not 
billed to Medicare. However, we do not believe that capture issues would differentially affect black 
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versus white patients, so comparisons between groups should be valid nonetheless. Fifth, with claims 
data, we could not separate physicians’ failure to prescribe aprepitant from patients not filling 
prescriptions. Thus, although we have documented the existence of disparities, we are unable to 
identify the underlying causes of the observed disparities using SEER-Medicare data. Future studies 
should attempt to use clinical data to ascertain whether the disparities identified here reflect 
disparities in NK1 prescriptions or fills. If black and white women are equally likely to be prescribed 
NK1s but less likely to fill these prescriptions, disparities may in fact reflect barriers related to 
affordability and accessibility.  
Although our study and others have pointed to racial disparities in use of antiemetics to 
prevent CINV, it remains unclear whether such disparities contribute to the disparate outcomes of 
black and white cancer patients. In breast cancer, black-white disparities in systemic treatment 
adherence and survival have been documented.[14, 38–40] Future studies should assess the role of 
treatment-induced side effect (including CINV) prevention and management in contributing to 
potential disparities not only in these observed outcomes but also in patients’ quality of life and 
cancer care experience.  
Our findings suggest that there may be a need for increased awareness among oncology 
providers of potential barriers to obtaining oral medications for CINV prevention. In addition, our data 
point to several possible explanations for and points of intervention to reduce disparities. For 
example, disparities may stem from low income and minority patients’ difficulty accessing or affording 
oral aprepitant, in which case the IV formulation may be more appropriate. Disparities may also stem 
from variation in prescribing, in which case provider-targeted interventions may help reduce 
disparities. To inform specific solutions, further research is needed to determine the relative 
contribution of patient-, provider-, and system-level factors to disparities.  
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Table 2. Aim 1 Sample Characteristics, by Race 
 White (N=1,015) 
Black 
(N=115) p-value 
Demographic Characteristics (%)    
Age at Cancer Diagnosis     
 65-66 20.7 25.2 0.7 
 67-68 24.7 24.4  
 69-71 25.1 22.6  
 72-91 29.4 27.8  
Marital Status at Diagnosisa    
 Married/Partnered 52.9 25.2 <0.0001 
 Non Married/Partnered 42.5 --  
 Unknown  4.6 --  
Median Household Income in Census Tract of 
Residencea    
 $0-32,791 21.6 53.0 <0.0001 
 $32,972-44,039 25.5 --  
 $44,040-58,436 -- 13.0  
 $58,437-188,340 27.1 --  
 Unknown  -- 0  
Proportion of Adult Residents with No High School 
Degree in  
Census Tract of Residencea 
   
 1.22-9.69% 27.4 -- <0.0001 
 9.70-16.57% 26.7 --  
 16.58-27.88% -- 30.4  
 27.89-75.17% 20.3 57.4  
 Unknown  -- 0  
Drug Copay Assistance (Medicaid Dual Eligibility 
and/or Part D Low Income Subsidy)    
 Yes 21.1 69.6 <0.0001 
 No 78.9 30.4  
Residence     
 Metropolitan County 74.8 82.6 0.06 
 Non-Metropolitan County 25.1 16.4  
U.S. Region     
 Northeast  19.4 20.0 <0.0001 
 Midwest  18.0 14.8  
 West  37.4 14.8  
 South  25.1 50.4  
Clinical Characteristics     
Year of Chemotherapy Initiationa,b    
 2007 28.9 31.3 0.9 
 2008 20.1 20.9  
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 2009 17.0 18.3  
 2010 14.8 --  
 2011 15.4 14.8  
 2012 3.8 --  
Charlson Comorbidity Scorea    
 0 78.4 75.7 0.2 
 1 17.2 --  
 >1 4.3 --  
Cancer Stage     
 Stage I 12.8 10.4 0.7 
 Stage II 53.6 56.5  
 Stage III 33.6 33.0  
Hormone Receptor Status     
 HR positive  67.0 62.6 0.5 
 HR negative  28.7 --  
 Unknown  3.7 --  
Tumor Gradea    0.3 
 Low 10.3 --  
 Intermediate 40.1 33.9  
 High  45.9 56.5  
 Unknown 4.3 --  
Lymph Node Involvementa    
 Yes  70.9 67.0 0.06 
 No  27.7 --  
 Unknown  1.4 --  
 
a Cells containing proportions that reflect Ns<11 or information that would allow Ns<11 to be derived 
have been suppressed (--) to protect patients’ identities  
b A small proportion of patients initiated chemotherapy in 2012 because we only have SEER data on 
patients diagnosed through December 2011. Thus, only patients who received chemotherapy within 
the first 6 months of 2012 are included in our sample.  
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Table 3. Unadjusted Associations of Race and Covariates with NK1 Use 
 NK1 Users (N=425)  
Aprepitant Users 
(N=290) 
Fosaprepitant Users 
(N=167) 
Demographic 
Characteristics (%)     
  
Race  p-value  p-value   p-value  
 Black     12.2 0.4 
 White 27.8 <0.01 15.7 <0.01 15.1  
Age at Cancer Diagnosis  41.0  29.2    
 65-66     14.2 0.4 
 67-68 39.7 0.4 28.9 0.2 17.9  
 69-71 42.3  29.0  13.8  
 72-91 41.5  30.5  13.3  
Marital Status at 
Diagnosis 35.8  23.6  
  
 Married/Partnered     
16.3 0.4 
 Non Married/Partnered 41.2 0.4 28.6 0.6 13.5  
 Missing 37.6  26.5  11.8  
Median Household 
Income in Census Tract 
of Residence 
    
  
 $0-32,791 31.4 <0.0001 19.2 <0.0001 14.3 0.6 
 $32,972-44,039 34.9  24.3  12.7  
 $44,040-58,436 39.6  26.1  15.0  
 $58,437-188,340 52.3  40.2  17.4  
Proportion of Adult 
Residents with No High 
School Degree in  
Census Tract of 
Residence1  
    
  
 1.22-9.69% 
51.8 <0.0001 39.0 <0.0001 
17.7 0.6 
 9.70-16.57% 38.1  26.7  13.9  
 16.58-27.88% 36.2  22.6  14.3  
 27.89-75.17% 31.2  20.6  13.2  
Drug Copay Assistance 
(Medicaid Dual Eligibility 
and/or Part D Low 
Income Subsidy) 
    
  
 Yes     10.2 0.01 
 No 28.2 <0.0001 20.4 <0.01 16.4  
Residence  43.6  30.4    
 Metropolitan County     15.3 0.4 
 Non-Metropolitan 
County 42.6 <0.001 30.2 <0.01 
13.0  
U.S. Region  30.4  20.3    
 Northeast      14.1 0.1 
 Midwest  50.0 <0.01 39.6 <0.001 16.5  
 West  50.0  22.0  11.8  
 South  39.0  30.2  17.9  
Clinical Characteristics  35.8  20.1    
Year of Chemotherapy       
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Initiation 
 2007     N/A <0.001 
 2008     N/A  
 2009 24.3 <0.0001 24.3 0.12 16.5  
 2010 30.3  29.8  20.9  
 2011 41.2  31.4  42.8  
 2012 43.6  32.5  60.5  
Charlson Comorbidity 
Score 65.9  26.0  
  
 0 76.7  14.3  14.8 0.4 
 1     12.9  
 >1 40.8 0.3 29.1 0.06 20.8  
Cancer Stage  35.6  25.3    
 Stage I 35.9  15.1  14.8 0.9 
 Stage II     14.6  
 Stage III 39.4 0.9 26.1 0.9 15.0  
 39.2  27.9    
Hormone Receptor 
Status  40.4  28.2  
  
 HR positive      13.2 0.03 
 HR negative      19.1  
 Status unknown/missing  44.5 0.1 27.4 0.7 10.4  
Tumor Grade  37.5  27.9    
 Low     15.0 0.4 
 Intermediate 40.7 0.3 31.2 0.6 12.5  
 High  36.3  26.9  16.4  
 Unknown/missing  42.4  28.1  --  
Lymph Node 
Involvement      
  
 Yes  39.8 0.2 28.6 0.3 14.3 0.3 
 No  38.2  25.2  15.3  
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Table 4. Adjusted Risks and Risk Ratios of Any NK1 Use, Aprepitant Use, and Fosaprepitant Use 
 Primary Models (adjusting for 
clinical characteristics only) 
Secondary Models (adjusted 
for SES-related variables) 
 Estimate and 95% CI Estimate and 95% CI 
Risk NK1 use, white 0.30 (0.20-0.44) 0.37 (0.21-0.63) 
Risk NK1 use, black 0.21 (0.13-0.33) 0.30 (0.16-0.55) 
Risk ratio NK1 use, black v. 
white 
0.68 (0.51-0.91) 0.81 (0.60-1.10) 
Risk aprepitant use, white 0.29 (0.18-0.46) 0.36 (0.18-0.55) 
Risk aprepitant use, black 0.15 (0.08-0.30) 0.24 (0.10-0.55) 
Risk ratio aprepitant use, black 
v. white 
0.54 (0.35-0.83) 0.66 (0.43-1.04) 
Risk fosaprepitant use, white 0.25 (0.13-0.50) 0.25 (0.09-0.70) 
Risk fosaprepitant use, black 0.21 (0.10-0.45) 0.26 (0.09-0.82) 
Risk ratio fosaprepitant use, 
black v. white 
0.82 (0.51-1.33) 1.05 (0.62-1.76) 
 
 
 
Table 5. Full Results of Primary Modified Poisson Regression Models, Adjusted Risk Ratios and 95% 
Confidence Intervals for NK1 Use 
 Any NK1 Use Aprepitant Use Fosaprepitant Use 
Demographic 
Characteristics     
Race     
 White 1.00 (REF) 1.00 (REF) 1.00 (REF)  
 Black 0.68 (0.51-0.91) 0.54 (0.35-0.83) 0.82 (0.51-1.33) 
Age at Cancer 
Diagnosis     
 65-66 1.00 (REF) 1.00 (REF) 1.00 (REF) 
 67-68 0.94 (0.87-1.29) 1.01 (0.77-1.31) 1.28 (0.91-1.83) 
 69-71 1.06 (0.87-1.29) 1.04 (0.80-1.35) 1.04 (0.71-1.52) 
 72-91 0.89 (0.73-1.09) 0.81 (0.62-1.08) 0.96 (0.67-1.37) 
Clinical 
Characteristics     
Year of Chemotherapy 
Initiation    
 2007 1.00 (REF) 1.00 (REF) -- 
 2008 1.24 (0.95-1.42) 1.20 (0.92-1.58) -- 
 2009 1.70 (1.32-2.19) 1.29 (0.97-1.71) 1.00 (REF) 
 2010 1.75 (1.36-2.26) 1.30 (0.97-1.74) 1.26 (0.81-1.95) 
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 2011 2.72 (2.20-3.38) 1.08 (0.79-1.48) 2.63 (1.83-3.78) 
 2012 3.15 (2.48-4.02) 0.67 (0.33-1.35) 3.66 (2.46-5.45) 
Charlson Comorbidity 
Score    
 0 1.00 (REF) 1.00 (REF) 1.00 (REF) 
 1 0.88 (0.73-1.07) 0.88 (0.68-1.15) 0.90 (0.62-1.29) 
 >1 0.84 (0.61-1.15) 0.56 (0.30-1.06) 1.10 (0.71-1.70) 
Cancer Stage     
 Stage I 1.00 (REF) 1.00 (REF) 1.00 (REF) 
 Stage II 0.98 (0.76-1.26) 1.06 (0.73-1.53) 1.04 (0.65-1.65) 
 Stage III 0.95 (0.71-1.28) 1.02 (0.67-1.56) 0.98 (0.57-1.69) 
HR Status     
 HR negative  1.00 (REF) 1.00 (REF) 1.00 (REF) 
 HR positive  0.80 (0.68-0.94) 0.91 (0.71-1.15) 0.64 (0.48-0.85) 
Tumor Grade     
 Low 1.00 (REF) 1.00 (REF) 1.00  
 Intermediate  0.88 (0.69-1.13) 0.86 (0.63-1.17) 0.75 (0.48-1.15) 
 High 0.92 (0.72-1.19) 0.90 (0.63-1.24) 0.73 (0.47-1.12) 
Lymph Node 
Involvement     
 No 1.00 (REF) 1.00 (REF) 1.00 (REF) 
 Yes  1.16 (0.95-1.42) 1.18 (0.88-1.58) 1.09 (0.77-1.55) 
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CHAPTER 5. EXAMINING RACIAL VARIATION IN ANTIEMETIC USE AND POST-
CHEMOTHERAPY HEALTHCARE UTILIZATION FOR NAUSEA AND VOMITING AMONG 
BREAST CANCER PATIENTS 
Introduction 
 In the United States, breast cancer is the most common malignancy among women.[1] Over 
the past two decades, advancements in early detection and treatment have improved breast cancer 
outcomes, leading to five-year survival rates of 99% for local-stage disease and 85% for regional-
stage disease.[2] With these advances, the goals of breast cancer care have expanded from treating 
the disease to preserving women’s quality of life (QOL) during treatment. QOL is conceptualized as a 
multidimensional measure of physical, functional, emotional, and social well-being.[3] The presence 
of symptoms related to breast cancer and its treatment is an important component of QOL.[4, 5] 
Thus, symptom management is increasingly recognized as critical to high-quality breast cancer 
care.[6–8]  
 Research suggests that cancer patients of minority race may receive inadequate symptom 
management. Studies have documented racial/ethnic disparities in outcomes related to symptom 
burden and severity,[9, 10] adequacy of pain treatment,[11–13] and patients’ perceived unmet need 
for supportive care.[14] Other studies have demonstrated that minority patients may underuse 
medications to control treatment-related symptoms. In particular, evidence suggests that black 
patients may be more likely than white patients to experience underuse of guideline-recommended 
antiemetic medications to prevent chemotherapy-induced nausea and vomiting (CINV), which cancer 
patients have consistently cited as a major and fearful concern.[15] Specifically, Samuel and 
colleagues found that among colorectal, lung, and prostate cancer patients being treated with 
chemotherapy in the Veterans Affairs system, black patients were less likely than white patients to 
use 5HT3 receptor antagonists.[16] Gomez and colleagues also found racial and income disparities in 
use of both 5HT3 antagonists and dexamethasone among lung cancer patients in Texas.[17] More 
recently, we documented disparities in use of NK1s, a newer and more potent class of antiemetics 
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recommended for use with highly emetogenic chemotherapy regimens among women with early-
stage breast cancer, a population that frequently receives highly emetogenic chemotherapy.[18] 
 In addition to the known implications for patients’ QOL, racial disparities in CINV prophylaxis 
may perpetuate well-documented disparities in other dimensions of breast cancer care. Namely, 
research has demonstrated that black women may be less likely to adhere to recommended 
chemotherapy regimens and schedules[19–22] and more likely to experience hospitalizations and 
acute illness during treatment with chemotherapy.[22] Others have suggested that minority women’s 
difficulty accessing medications to control treatment-related side effects may help explain differential 
treatment experiences.[23] However, the link between disparities in side effect control and treatment 
experiences of breast cancer patients has not been empirically studied.  
 With the objective of furthering understanding of how racial disparities in CINV management 
may contribute to racial disparities in breast cancer treatment experiences, we assessed racial 
differences in post-chemotherapy healthcare utilization related to CINV, including use of inpatient, 
emergency department, or outpatient services. We also assessed the role of prophylactic NK1 use in 
potentially attenuating these differences. Finally, we assessed racial differences in any post-
chemotherapy healthcare utilization overall and for other common breast cancer treatment-induced 
side effects to determine whether any potential differences in utilization for CINV could be explained 
by differential use of services more broadly.  
Methods  
Data  
We used the National Cancer Institute’s Surveillance Epidemiology and End Result (SEER) 
database linked with Medicare fee-for-service claims from 2006 to 2012. The SEER program consists 
of population-based cancer registries and represents 28% of the population with cancer. SEER data 
are merged with fee-for-service Medicare claims.[24] Data for our analysis came from the Prescription 
Drug Event records, the Medicare Provider Analysis and Review (MEDPAR) file for inpatient services, 
the Hospital Outpatient Standard Analytic file for outpatient facility services, the 100% 
Physician/Supplier file for physicians’ services, and the Durable Medical Equipment (DME) File. 
52 
Our study was conducted in accordance with a SEER-Medicare data use agreement and was 
approved by the Institutional Review Board at the University of North Carolina at Chapel Hill. 
Sample 
We included women aged 65 years and older who were diagnosed with stage I, II, or III 
breast cancer between January 1, 2007, and December 31, 2011. Eligible women were: (1) not 
diagnosed at autopsy or death; (2) continuously enrolled in Medicare Parts A and B for 6 months 
before and 12 months after diagnosis; (3) continuously enrolled in Medicare Part D for 12 months 
after diagnosis; and (4) not enrolled in an HMO for 6 months before and 12 months after diagnosis. 
There were 27,160 women meeting these criteria. From this sample, we restricted our analysis to 
women who received surgery (mastectomy or breast-conserving surgery) and initiated chemotherapy 
within 6 months of diagnosis (n=4,651). The analysis was further restricted to women whose first 
cycle of adjuvant chemotherapy included an anthracycline and cyclophosphamide (n=1,569) because 
guidelines have consistently recommended use of an NK1 for these regimens throughout the study 
period.[25–29] Due to of the small proportion of non-black minorities (n=118), the study was restricted 
to black and white women (n=1,451). Finally, because Part D claims are available starting on January 
1, 2007, women in our sample initiated chemotherapy on or after February 1, 2007 (n=1130). This 
enabled us to observe Part D claims for antiemetics in the 30 days before chemotherapy initiation.  
Variables 
The primary outcome was post-chemotherapy healthcare use, measured as any inpatient or 
outpatient claims (including emergency department claims) in the 14 days after the first 
chemotherapy infusion. We were specifically interested in CINV-related use, identified by claims with 
an associated diagnosis of nausea and vomiting (ICD-9 codes 787.0-787.02), volume depletion (ICD-
9 code 276.5), dehydration (ICD-9 code 276.51), or hypovolemia (ICD-9 code 276.52) in the 14 days 
after the first chemotherapy infusion. We chose 14 days as the window of observation because 
adjuvant chemotherapy regimens for breast cancer should be given no more frequently than every 14 
days.[30]  
The main independent variables in our analysis were race (black or white), as reported in the 
Patient Entitlement and Diagnosis Summary File (PEDSF) of the SEER-Medicare data, and 
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prophylactic NK1 use. NK1 users were defined as having a Medicare Part D claim for aprepitant (oral 
formulation), as identified by the drug name, in the 30 days before or on the day of chemotherapy 
initiation. Alternatively, they had a Part B claim for aprepitant in the 30 days before or on the day of 
chemotherapy initiation, as identified using Health Care Common Procedure Coding System codes 
(J8501) and as recorded in the outpatient, physician services, or durable medical equipment claims 
files. Finally, NK1 users could have a claim for fosaprepitant (IV formulation) (C9242, J1453) on the 
day of chemotherapy initiation, as recorded in the outpatient or physician services files. We focused 
on the first cycle of chemotherapy because we were interested in measuring use of NK1s for CINV 
prophylaxis rather than use that may be in response to symptoms experienced during a previous 
cycle.  
Covariates included patients’ demographic and clinical characteristics: age at diagnosis, 
American Joint Committee on Cancer stage, tumor grade, hormone receptor status, lymph node 
involvement, comorbid illness (calculated using the Klabunde modification of the Charlson score 
based on patients’ Medicare Part A and B claims pre-diagnosis),[31] and year of chemotherapy 
initiation. We also included information on patients’ marital status. Area-level measures of 
socioeconomic status (SES) included census tract–level high school completion rate and median 
income, obtained from the 2000 census. Geographic variables were U.S. region of residence and 
extent of urbanization in patients’ neighborhoods.  
Statistical Analysis  
We examined the distribution of patient characteristics between racial groups using chi-
squared tests. To directly estimate risk ratios with robust error variance, we used modified Poisson 
regression [32] to assess the relationships between race, NK1 use, and post-chemotherapy 
healthcare utilization, controlling for relevant patient characteristics. We present unadjusted risk ratios 
(RR) and adjusted risk ratios (aRR) with 95% confidence intervals (CI) for post-chemotherapy 
healthcare utilization, comparing black and white women and NK1 users versus non-users.  
Accounting for SES. The Institute of Medicine (IOM) defines racial healthcare disparities as 
differences in treatment not justified by racial differences in health status or preferences.[33] Analytic 
approaches to implement this definition use statistical models that control only for differences in 
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health status (e.g., comorbidity, age) and clinical need (e.g., tumor characteristics) and, if available, 
preferences for care between racial groups.[16, 34, 35] This approach recognizes the mediating role 
of an individual’s SES and SES-related factors, that is, minorities tend to have lower SES profiles 
than whites and such differences can impact care received. However, such approaches do not adjust 
for SES-related factors because doing so may reduce the estimated independent effect of race on 
care and give a false picture of the care experience of racial minority patients.  
Consistent with the IOM definition of healthcare disparities, our primary models adjusted for 
clinical characteristics (age at diagnosis, year of chemotherapy initiation, tumor characteristics, and 
medical comorbidity).[35] We did not adjust for census tract–level measures of SES or in our primary 
models; neither did we adjust for other potential mediators of disparities, namely geographic factors 
(U.S. region of residence and metropolitan versus non-metropolitan residence) and marital status. 
However, because it is important to understand where disparities in care might arise, we conducted 
secondary analyses to assess whether differences in census tract–level SES, marital status, or 
geography attenuated potential racial differences in utilization.  
Sensitivity Analyses  
Sensitivity analyses restricted the outcome measurement window to 7 days post-
chemotherapy administration and restricted CINV-related utilization to claims with a primary or 
secondary diagnosis related to CINV.  
Results 
Among the 1,130 women who met our eligibility criteria, 1,015 (89.8%) were white and 115 
(10.2%) were black. Compared to white women, black women were more likely to be single (71% 
versus 42%, p<0.0001). There were also racial differences in census tract–level income and 
education and U.S. region of residence (p<0.0001). Regarding CINV prophylaxis, black women were 
10.9% less likely to use an NK1 (p<0.05) (Table 6). Overall, 91% of women had outpatient visits in 
the 14 days following their first chemotherapy infusion and 23% of women were treated for CINV. 
CINV-related utilization consisted largely of claims for outpatient visits (22%); only 2% of women had 
ED or inpatient claims related to CINV.  
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CINV-Related Utilization  
In unadjusted analysis, compared to white women, black women had a 37% decreased risk 
of experiencing any CINV-related utilization (RR: 0.63, 95% CI: 0.40-0.99) (Table 2). Racial 
differences in CINV-related utilization did not persist in our primary model adjusting for clinical 
characteristics (aRR: 0.66, 95% CI: 0.42-1.04, p=0.07) or in the secondary model adjusting for clinical 
characteristics along with SES, marital status, and geographic variables (aRR: 0.69, 0.42-1.14, 
p=0.12). In both adjusted models, estimates were similar to the unadjusted results, but they were no 
longer statistically significant due to widening confidence intervals.  
Patients’ NK1 use was positively associated with CINV-related utilization in unadjusted and 
adjusted models. Compared to women who did not receive an NK1 for the prevention of CINV, 
women who did experienced an increased risk of CINV-related utilization (aRR: 1.34, 95%CI: 1.07-
1.68, p=0.01). This positive relationship persisted among white women (aRR: 1.33, 95%CI: 1.06-1.69, 
p=0.01) but it was not statistically significant among black women (aRR: 1.08, 95% CI: 0.34-3.41, 
p=0.90) (data not shown).  
 In the sensitivity analysis restricting CINV-related utilization to claims with a primary or 
secondary (versus any) diagnosis code related to CINV, the racial difference in utilization was larger 
than in the primary model, but still statistically non-significant (aRR: 0.52, 95% CI: 0.26-1.05; p=0.07). 
In an additional sensitivity analysis restricting the window of observation for CINV-related claims to 7 
days post-chemotherapy initiation, estimates were similar to those of the main model (aRR: 0.61, 
95% CI: 0.25-1.47, p=0.30).  
Other Post-Chemotherapy Utilization  
 In analyses examining racial differences in any post-chemotherapy healthcare utilization, we 
found no differences in either unadjusted or adjusted models (aRR: 0.95, 95%CI: 0.89-1.03, p=0.21) 
(Table 7). There were also no statistically significant racial differences in women’s outpatient 
utilization for other common chemotherapy-induced side effects. Specifically, black women were no 
less likely than white women to receive treatment for neutropenia (aRR: 0.90, 95% CI: 0.71-1.16, 
p=0.42) or fatigue (aRR: 0.45, 95% CI: 0.14-1.44, p=0.18). 
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Discussion 
 We observed possible racial variation in use of outpatient services for CINV during the first 
cycle of highly emetogenic chemotherapy, with black women being less likely to receive CINV-related 
care in the post-chemotherapy period. This finding was counter to our hypothesis that black women 
would be more likely to experience CINV-related utilization because of evidence of potential underuse 
of NK1s for CINV prophylaxis among black patients. Instead, in this SEER-Medicare sample, black 
women were at lower risk for both using an NK1 and for receiving treatment for CINV. Although the 
racial difference in CINV-related utilization was not statistically significant after adjustment for 
covariates, estimates were still consistent with lower utilization among black patients. This racial 
difference did not extend to any post-chemotherapy outpatient utilization. There are several potential 
explanations for our findings.  
 One explanation for racial variation in cancer-related health services use is that black cancer 
patients are less likely to access care in general,[33] for example, adjuvant treatment for breast 
cancer.[36] Similar patterns have been observed in other cancers, with black patients more likely to 
refuse lung cancer treatment.[37] However, it seems unlikely that racial differences in care-seeking 
behavior fully explain the variation we observed because our sample is limited to women who 
underwent surgery and initiated adjuvant chemotherapy. Moreover, we observed no racial variation in 
the use of any outpatient services during the 14 days following chemotherapy initiation. This suggests 
that even among women who chose to undergo multi-model therapy, differences in CINV-related 
healthcare utilization exist.  
 Because racial differences in general or cancer care–seeking behavior do not appear to 
explain racial variation in CINV-related services use, it may be that the variation we observed is 
specific to CINV or symptom management. There are two reasons black women may be less likely to 
have claims with diagnosis codes related to CINV. First, black and white women may be at equal risk 
of experiencing CINV but black women may be less likely to report this experience to their 
providers.[38] Differential reporting could result from differential thresholds for reporting symptoms 
across demographic or cultural characteristics.[39] Alternatively, minority and low-income women 
may have competing health or social concerns that affect their likelihood of reporting symptoms 
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and/or prioritizing their management.[39] Others have suggested that vulnerable populations, 
including minorities, may receive suboptimal care due to decreased self-efficacy, defined as patients’ 
perceived ability in obtaining needed information and attention regarding their medical concerns.[40] 
In a study by Maly and colleagues, perceived self-efficacy was positively associated with nausea 
resolution in a cohort of low-income women with breast cancer.[41] In any case, it is ultimately the 
physician’s awareness of symptoms that leads to discussion of treatment options with the patient, 
thereby facilitating symptom resolution. Thus, if minority patients are less likely to mention symptoms 
for any reason, they may be less likely to receive treatment for their symptoms, which could explain 
the lower incidence of CINV-related claims for black women in our data. A second potential 
explanation is that the black women in our sample may differ from white women with respect to 
unmeasured factors (e.g., body mass index), which could affect the incidence of treatment-induced 
side effects like CINV.[39, 42, 43] Higher rates of obesity could also lead to chemotherapy under-
dosing among black women,[44] which could decrease the incidence of side effects like CINV.  
 Reporting bias could also occur at the provider level. Our measures of healthcare utilization 
rely on providers’ coding of diagnoses. If providers are less likely to code nausea and related 
conditions among black patients, for example, due to competing or more pressing health concerns, 
rates of CINV could appear artificially low in black patients.  
 We did not observe statistically significant racial differences in patients’ receipt of treatment 
for fatigue or neutropenia, side effects commonly experienced among breast cancer patients 
including those in our sample. Our lack of observation of a statistically significant relationship 
between race and fatigue-related services use may be due to our small sample size because 
estimated risk ratios were consistent with substantial racial variation. Specifically, black patients were 
55% less likely than white patients to have claims related to fatigue. Racial differences in use of 
services related to neutropenia were smaller (10%), however neutropenia is often not symptomatic 
and thus more commonly diagnosed through routine post-chemotherapy blood testing. Therefore, it is 
not clear whether neutropenia-related claims capture testing for the condition or patients’ experience 
of neutropenia-related infection.  
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The positive association between prophylactic NK1 use and CINV-related utilization was also 
surprising. A possible explanation is that we inadvertently captured claims with associated CINV 
diagnosis codes used to justify the prophylactic administration of antiemetics. This seems unlikely, 
however, because our observation window begins the day after chemotherapy initiation and extends 
for 14 days. Adjuvant chemotherapy regimens for breast cancer should be given no more frequently 
than every 14 days; thus, we should not have captured claims for antiemetic administration during a 
women’s second cycle of chemotherapy. Therefore, we suspect confounding—specifically 
confounding by indication—may account for this relationship. For example, patients’ (or their 
providers’) level of concern about CINV might help explain why patients who receive NK1s are also 
more likely to subsequently receive care related to the side effect. Our data suggest that white 
patients may be more likely to both use NK1s to prevent CINV and be treated for CINV, raising the 
question of whether black women are not being identified as being in need of CINV prevention and 
treatment. It is also possible that black women are concentrated within providers or systems where it 
may be more difficult to access high-quality cancer care,[45] including medications to prevent side 
effects and services to address them.[45] Black women may also experience access barriers that 
make both obtaining NK1s and side effect–related care more difficult.  
 Our study has several limitations. First, we restricted our cohort to fee-for-service Medicare 
beneficiaries with Part D coverage. It is unknown whether our findings generalize to younger women, 
Medicare beneficiaries enrolled in an HMO, or women without prescription drug coverage through 
Part D. Second, we focused on NK1 receptor antagonist use as an indicator of CINV prophylaxis. We 
did so because NK1s are, according to guidelines, effective only in combination with two other less 
potent antiemetics (5HT3 antagonists and dexamethasone). However, our measure did include less 
potent antiemetics without an NK1. It is possible that patients who used an NK1 did not use it in 
combination with less potent antiemetics. Third, we were unable to account for patients’ need for 
CINV-related care (i.e., their clinical experience with CINV). Fourth, our use of claims data prevented 
our ability to measure other clinically meaningful outcomes, for example, early termination of or 
withdrawal from chemotherapy, because it is not possible to determine a woman’s intended 
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chemotherapy regimen or duration. Finally, only 115 black women met our study inclusion criteria, 
which might have resulted in our lacking statistical power for some comparisons.  
 These limitations notwithstanding, we present novel data about possible racial variation in 
receipt of CINV-related care following the first cycle of highly emetogenic adjuvant chemotherapy for 
early-stage breast cancer. This variation may point to racial differences in women’s experience with 
CINV and their need for its treatment, their preferences for seeking care related to CINV, or their 
ability to obtain needed care for CINV and potentially other symptoms. Thus, our data suggest that 
there may be a need for increased awareness and assessment of common side effects during post-
treatment visits to ensure patients’ supportive care needs are met. Future research should assess 
whether black women’s relatively lower use of CINV-related medications and services is consistent 
with their informed preferences or whether they may be experiencing barriers to access of needed 
services. In addition, determining the role of women’s side effect experiences in contributing to 
disparities in important breast outcomes such as patient-reported QOL and treatment adherence 
represents a novel area for future research.  
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Table 6. Sample Characteristics, by Race 
 White Black 
Number of Patients 1,015 115 
Demographic Characteristics (%)   
Age at Cancer Diagnosis    
 65-66 20.7 25.2 
 67-68 24.7 24.4 
 69-71 25.1 22.6 
 72-91 29.4 27.8 
Marital Status at Diagnosisa   
 Married/Partnered 52.9 25.2 
 Non Married/Partnered 42.5 -- 
 Unknown  4.6 -- 
Median Household Income in Census Tract of 
Residencea   
 $0-32,791 21.6 53.0 
 $32,972-44,039 25.5 -- 
 $44,040-58,436 -- 13.0 
 $58,437-188,340 27.1 -- 
 Unknown  -- 0 
Proportion of Adult Residents with No High School 
Degree in Census Tract of Residencea 
  
 1.22-9.69% 27.4 -- 
 9.70-16.57% 26.7 -- 
 16.58-27.88% -- 30.4 
 27.89-75.17% 20.3 57.4 
 Unknown  -- 0 
Residence    
 Metropolitan County 74.8 82.6 
 Non-Metropolitan County 25.1 16.4 
U.S. Region    
 Northeast  19.4 20.0 
 Midwest  18.0 14.8 
 West  37.4 14.8 
 South  25.1 50.4 
Clinical Characteristics    
Year of Chemotherapy Initiationa,b   
 2007 28.9 31.3 
 2008 20.1 20.9 
 2009 17.0 18.3 
 2010 14.8 -- 
 2011 15.4 14.8 
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 2012 3.8 -- 
Charlson Comorbidity Scorea   
 0 78.4 75.7 
 1 17.2 -- 
 >1 4.3 -- 
Cancer Stage    
 Stage I 12.8 10.4 
 Stage II 53.6 56.5 
 Stage III 33.6 33.0 
Hormone Receptor Statusa    
 HR positive  67.0 62.6 
 HR negative  28.7 -- 
 Unknown  3.7 -- 
Tumor Gradea    
 Low 10.3 -- 
 Intermediate 40.1 33.9 
 High  45.9 56.5 
 Unknown 4.3 -- 
Lymph Node Involvementa   
 Yes  70.9 67.0 
 No  27.7 -- 
 Unknown  1.4 -- 
CINV Prophylaxis   
NK1 Receptor Antagonist Use    
 Yes 38.7 27.8 
 No 61.3 72.2 
 
 
a Cells containing proportions that reflect Ns<11 or information that would allow Ns<11 to be derived 
have been suppressed (--) to protect patients’ identities  
b A small proportion of patients initiated chemotherapy in 2012 because we only have SEER data on 
patients diagnosed through December 2011. Thus, only patients who received chemotherapy within 
the first 6 months of 2012 are included in our sample.  
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Table 7. Unadjusted and Adjusted Associations of Race with Post-Chemotherapy Healthcare 
Utilization 
 Risk and 95% Confidence Intervals Risk Ratios and 95% Confidence 
Intervals, 
Black v. White 
 Unadjusted models Models adjusted for 
clinical characteristics  
Unadjusted 
models 
Models adjusted 
for clinical 
characteristics 
 White Black White Black   
CINV-Related 
Utilization  
      
Any 
0.23 
 (0.21-
0.26) 
0.15 
(0.10-
0.23) 
0.24  
(0.14-
0.42) 
0.16  
(0.08-
0.32) 
0.63a 
 (0.40-0.99) 
0.66 (0.42-1.04) 
Outpatient visits 
0.23  
(0.21-
0.26) 
0.15 
(0.09-
0.23) 
0.23  
(0.13-
0.41) 
0.15 
(0.08-
0.311) 
0.64a 
(0.41-1.01) 
0.67 (0.43-1.06) 
ED visits & inpatient 
admissions 
0.03  
(0.02-
0.05) 
0.03 
(0.01-
0.09) 
N/Ab N/Ab 1.07 
(0.39-2.97) 
N/Ab 
       
Any Post-
Chemotherapy 
Utilization  
0.91  
(0.89-
0.93) 
0.87  
(0.81-
0.93) 
0.88  
(0.80-
0.96) 
0.84 
 (0.74-
0.94) 
0.95  
(0.89-1.03) 
0.95 
 (0.89-1.03) 
       
Utilization For Other 
Side Effects  
      
Fatigue  
0.06  
(0.05-
0.08) 
0.03  
(0.01-
0.08) 
0.02 
(0.00-
0.09) 
0.01  
(0.00-
0.07) 
 0.43  
(0.14-1.36)  
0.45 
(0.14-1.44) 
Neutropenia  
0.41  
(0.38-
0.44) 
0.37  
(0.30-
0.47) 
0.35  
(0.24-
0.52) 
0.32 
(0.21-
0.50) 
0.92  
(0.72-1.18) 
0.90 
 (0.71-1.16) 
a Estimates in bold are marginally statistically significant (p=0.05)  
b Only unadjusted models for ED visits and inpatients admissions were run due to very low frequency 
of this outcome, resulting in insufficient cell sizes  
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CHAPTER 6. IMPACT OF DRUG FORMULATION CHANGES ON POTENT ANTIEMETIC USE 
AND DISPARITIES AMONG MEDICARE BENFICIARIES WITH BREAST CANCER 
Introduction  
 Chemotherapy-induced nausea and vomiting (CINV) is a major concern for patients 
beginning cancer treatment.[1] Poorly controlled CINV can have severe physiological consequences, 
leading to a deterioration of a patient’s functional condition and quality of life (QOL).[2–4] 
Furthermore, uncontrolled CINV can lead to treatment interruptions or withdrawal from potentially 
beneficial chemotherapy.[4, 5] Therefore, CINV control is critical to high-quality cancer care.  
Clinical practice guidelines from oncology professional organizations recommend the use of 
antiemetic drugs to prevent CINV.[6–8] For several years, the guidelines have recommended 
prophylactic use of the most potent class of antiemetic, neurokinin-1 receptor antagonists (NK1s), for 
patients receiving chemotherapy with a high likelihood of CINV. Until 2008, aprepitant, an orally 
administered NK1 designed to be taken on the first three days of the chemotherapy cycle (i.e., on 
infusion day and the two subsequent days) was the only NK1 available for CINV prophylaxis. There 
are several barriers to aprepitant use. Namely, because most private practices and many hospital-
based practices do not dispense oral drugs, patients must obtain aprepitant from pharmacies and 
bring it to their infusion sites on treatment days. Reimbursement rules for Medicare beneficiaries have 
further complicated access to NK1s because the orally administered drug may be reimbursed under 
Part B (outpatient medical benefit) or Part D (outpatient prescription drug benefit), which vary in 
access and cost-sharing requirements. Under Medicare Part B, providers can only write prescriptions 
for an antiemetic for a single three-day cycle at a time. With Part D plans, patients may encounter 
prior authorizations and quantity limitations.[9] Moreover, the drug is expensive. Estimates suggest 
that three aprepitant capsules cost over $500 under Medicare Part D, and patients may be 
responsible for 25%- to 50% of that cost.[10] Our previous study of breast cancer patients initiating 
highly emetogenic chemotherapy suggests that barriers to aprepitant use may disproportionately 
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affect minority patients—we found that black women were 42% less likely than white women to use 
aprepitant.[11]  
In April 2008, the FDA approved fosaprepitant, an intravenous (IV) formulation of aprepitant, 
for the first of the three daily aprepitant doses. The introduction of fosaprepitant allowed for combined 
use of the IV and oral formulations by giving providers the option to administer fosaprepitant on day 
one of the cycle and prescribe oral aprepitant for at-home use on days two and three. In theory, 
combined IV/oral use was an effective alternative for patients who either failed to obtain aprepitant 
prior to infusion day or forgot to bring the first aprepitant dose to the clinic on infusion day. In practice, 
however, controversial coverage decisions by Medicare discouraged combined use of the IV and oral 
formulations by limiting coverage fosaprepitant on day one to cases where providers could document 
a patient’s previous failure to achieve CINV control with the oral formulation. This may have limited 
providers’ adoption of the IV formulation.[9]  
NK1 formulations further evolved in 2010, when a clinical trial demonstrated that a larger, 
single dose of fosaprepitant could be used as a full replacement for the three-day antiemetic regimen 
[12]; the FDA approved the new dosage. When administered as full replacements for oral drugs, IV 
antiemetics may be more convenient for patients because they minimize scheduled medication 
administration at home. In addition, IV antiemetics may be more affordable for patients. Unlike oral 
antiemetics, which are sometimes covered by Medicare Part D, IV antiemetics are exclusively 
covered by Medicare Part B, under which most Medicare beneficiaries have supplemental insurance 
coverage to assist with their out-of-pocket costs.[13] For these reasons, the approval of single-dose 
fosaprepitant was expected to decrease the proportion of cancer patients receiving suboptimal CINV 
prophylaxis. [14]  
Analyses of recent data are needed to evaluate the impact of formulation and reimbursement 
changes on use and disparities in use of NK1s to prevent CINV. Our objective was to assess 
changes over time in NK1 use among women with early-stage breast cancer, a population that 
frequently receives highly emetogenic chemotherapy. Because our previous study showed 
substantial racial disparities in women’s NK1 use,[11] we assessed changes in overall and 
formulation-specific utilization among black and white women over time. We hypothesized that 
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fosaprepitant availability, particularly the introduction of single-dose fosaprepitant, would lead to 
increased NK1 use for both black and white patients. We also hypothesized that by providing a more 
accessible and potentially more affordable alternative to three-day oral aprepitant the introduction of 
single-dose fosaprepitant may have helped reduce racial disparities in NK1 use.  
Methods 
Data  
We used the National Cancer Institute’s Surveillance Epidemiology and End Result (SEER) 
database linked with Medicare fee-for-service claims from 2006 to 2012. The SEER program consists 
of population-based cancer registries and represents 28% of the population with cancer. SEER data 
are merged with fee-for-service Medicare claims to allow for assessments of health services use 
among Medicare beneficiaries with cancer.[15] Our study was conducted in accordance with a SEER-
Medicare data use agreement and was approved by the Institutional Review Board at the University 
of North Carolina at Chapel Hill. 
Sample 
We included women aged 65 years and older who were diagnosed with stage I, II, or III 
breast cancer between January 1, 2007, and December 31, 2011. Eligible women were: (1) not 
diagnosed at autopsy or death; (2) continuously enrolled in fee-for-service Medicare Parts and A and 
B for 6 months before and 12 months after diagnosis; and (3) continuously enrolled in Medicare Part 
D for 12 months after diagnosis. From the 27,160 women meeting these criteria, we restricted our 
sample to women who received surgery (mastectomy or breast-conserving surgery) and initiated 
chemotherapy within 6 months of diagnosis (n=4,651). The analysis was further restricted to women 
whose first cycle of adjuvant chemotherapy included an anthracycline and cyclophosphamide 
(n=1,569) because guidelines have consistently recommended use of an NK1 for these regimens 
throughout the study period.[6–8, 16, 17] Because of the small proportion of non-black minorities 
(n=118), the study was restricted to black and white women (n=1,451). Finally, we restricted our 
sample to women who initiated chemotherapy between February 1, 2007, and December 31, 2011, to 
observe Part D claims for antiemetics in the 30 days before chemotherapy initiation and to allow for 
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12 months of follow-up. These restrictions resulted in a final sample of 1,087 women. A CONSORT 
diagram is displayed in Figure 3.  
Variables  
Our outcome was patients’ use of an NK1 during the first cycle of highly emetogenic adjuvant 
chemotherapy (containing an anthracyline and cyclophosphamide). NK1 users were defined as 
having a Medicare Part D claim for aprepitant (oral formulation), as identified by the drug name, in the 
30 days before or on the day of chemotherapy initiation. Alternatively, they had a Part B claim for 
aprepitant in the 30 days before or on the day of chemotherapy initiation, as identified using Health 
Care Common Procedure Coding System codes (J8501) and as recorded in the outpatient, physician 
services, or durable medical equipment claims files. Finally, NK1 users could have a claim for 
fosaprepitant (IV formulation) (C9242, J1453) on the day of chemotherapy initiation, as recorded in 
the outpatient or physician services files.  
Our exposure of interest was year of adjuvant chemotherapy initiation. Specifically, we were 
interested in changes in likelihood of NK1 use in 2009, following the FDA’s initial approval of 
fosaprepitant, and in 2011, following the introduction and approval of single-dose fosaprepitant. 
Patient race (black or white) was measured as reported in the Patient Entitlement and Diagnosis 
Summary File of SEER-Medicare. Patients’ CINV risk is determined primarily by their chemotherapy 
regimen.[6] Thus our analyses included a small number of covariates related to patients’ health 
status, namely, patient age, comorbidity burden, and cancer stage.  
Statistical Analysis  
We compared the distributions of patient characteristics between racial groups using chi-
squared tests. To directly estimate relative risks with robust error variance, we used modified Poisson 
regression,[18] estimating changes in NK1 use separately by chemotherapy initiation year. To 
estimate how changes in NK1 use differed between racial groups, we assessed changes in use of 
any NK1 and formulation-specific use among black and white patients separately, between 2007 and 
2011. We present risks ratios and adjusted risk ratios (aRR) with 95% confidence intervals (CI) for 
NK1 use.  
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Consistent with the IOM’s approach to measuring healthcare disparities, which recognizes 
the mediating role of an individual’s socioeconomic status (SES) and related factors, our models did 
not attempt to adjust for SES because doing so may reduce or eliminate the estimated independent 
effect of race on care, giving a false picture of the experience of vulnerable patients.[19] Moreover, 
SEER-Medicare includes only area-level measures of socioeconomic status (SES) (e.g., census 
tract–level median income), which may misclassify individuals’ SES, particularly for minorities.[20, 21]  
Sensitivity Analysis  
 To account for women’s potential previous experience with chemotherapy and CINV, our 
primary analysis was limited to women whose first cycle of chemotherapy included an anthracycline 
and cyclophosphamide. In sensitivity analysis we expanded the cohort to women initiating their first 
anthracycline and cyclophosphamide containing cycle without requiring this treatment to be the first 
chemotherapy received (N=1,176). Results from this sensitivity analysis were consistent with the 
primary analysis and are not shown.  
Results  
Our sample included 976 white women and 111 black women. There were no racial 
differences in health or tumor-related characteristics (Table 8). Compared to white women, black 
women were 10% less likely to use any NK1 over the study period (p=0.03) and 11% less likely to 
use aprepitant (p=0.01). There were no statistically significant differences by race in overall 
fosaprepitant use (Table 8).  
Models adjusted for health characteristics also show NK1 use increasing over time for both 
white and black patients (Table 8). Patients of both racial groups were more than twice as likely to 
use an NK1 in 2011 compared to 2007 (aRR for white patients: 2.67, 95% CI: 2.13-3.35; aRR for 
black patients: 2.54, 95% CI: 1.03-6.25). However, racial gaps have persisted. In 2007, the likelihood 
of NK1 use was 0.24 for white patients and 0.13 for black patients; increasing to 0.64 and 0.32 for 
white and black patients, respectively, by 2011 (Table 9). For each individual year, racial differences 
in likelihood of NK1 use were large but not statistically significant (Figure 3).  
Among white patients, the likelihood of NK1 use increased by 11% between 2008 and 2009 
and by 23% between 2010 and 2011. Aprepitant use specifically increased from 0.20 to 0.28 between 
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2007 and 2010. The proportion of white patients using NK1s continued to increase between 2010 and 
2011, driven by an increase in the likelihood of fosaprepitant use from 0.20 to 0.44, while aprepitant 
use fell (Table 9).  
Among black patients, use of NK1s increased by 8% between 2008 and 2009 and between 
2010 and 2011 (see Table 9). For black patients, the formulation-specific models did not show 
statistically significant changes in likelihood of aprepitant or fosaprepitant use over time. Descriptively, 
black patients’ increasing likelihood of fosaprepitant use, which rose from 0.09 in 2009 to 0.31 in 
2011, appears to explain the increase in any NK1 use over time for black patients because aprepitant 
use did not increase over time for this group (see Table 9).  
Discussion  
Changes in the formulation of and reimbursement for fosaprepitant had the potential to 
increase NK1 use for both black and white patients as well as to reduce racial disparities in NK1 use. 
Specifically, with the availability of a more accessible and affordable alternative to three-day oral 
aprepitant, we hypothesized that: (1) overall use of NK1 would increase and (2) disparities in NK1 use 
by patients who may experience cost or access barriers to prescription medication use (e.g., minority 
patients) would decrease.[22–24] In our sample of Medicare beneficiaries initiating highly emetogenic 
chemotherapy for early-stage breast cancer, NK1 use increased substantially for both black and white 
patients between its initial approval in 2008 and 2011. This increase suggests that, particularly after 
single-dose fosaprepitant was introduced in 2010 as an alternative to three-day aprepitant, providers 
recognized the IV drug as a more convenient option for all patients.[9] That NK1 use has improved for 
all patients in our sample is encouraging and suggests that over time more patients are receiving 
adequate prevention of CINV. However, the observed persistent racial gap indicates that the CINV 
prevention needs of many black women are not being met. Thus, targeted efforts to increase NK1 
use among black patients may be needed. 
To inform interventions to reduce these disparities, future research should assess the 
contribution of provider- versus patient-level barriers to NK1 use. For example, black women may be 
more likely to receive care within lower-performing systems[25] where providers do not routinely 
prescribe NK1s in accordance with clinical guidelines[26] either because the systems’ antiemetic 
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order sets do not align with guidelines or individual prescribers are unfamiliar with the guidelines.[27] 
Second, black women and white women may be equally likely to be prescribed an NK1, but black 
women may be less likely to fill a prescription for aprepitant due to financial[22] or other access 
barriers.[23, 24] In our previous SEER-Medicare study of racial disparities in antiemetic use among 
breast cancer patients, disparities in any NK1 and aprepitant use appeared to be partly explained by 
SES differences between black and white women.[11] These SES differences could translate into 
differential access to high-quality providers and/or differential ability to access pharmacies[23, 24] and 
to afford expensive prescription drugs.[22]  
One previous analysis of cancer care quality indicators within the Veterans Affairs (VA) 
system concluded that hospital-level variation fully explained racial disparities in guideline-concordant 
use of 5HT3 receptor antagonists for CINV prophylaxis.[26] However, the primary role of hospital-
level variation in explaining disparities in antiemetic use could be unique to the VA system, which 
offers more comprehensive drug coverage than any other public or private payer in the United States, 
potentially obviating patient-level cost barriers to oral antiemetic use.[28] Future studies of cancer 
patients in the general population should investigate the role of site of care in explaining disparities in 
antiemetic use. If disparities appear to reflect differential prescribing by site of care, provider- or 
system-level interventions may be appropriate. Previous research has demonstrated that several 
institution-wide strategies, including adoption of institutional guidelines[29–31] and implementation of 
guidelines through use of physician audit and feedback,[30, 31] opinion leaders, and preprinted 
antiemetic orders[31] may be effective strategies for improving providers’ antiemetic prescribing.  
Understanding patient-level contributors to disparities will require data about both providers’ 
prescribing and patients’ receipt of NK1s. If black and white patients are equally likely to be 
prescribed an NK1 but black patients are less likely to fill aprepitant prescriptions, patient-level 
barriers must be targeted to reduce persistent disparities in NK1 use. For example, if disparities in 
NK1 use result from patients’ differential ability to afford aprepitant,[22, 32] interventions might 
encourage conversations between oncologists and patients regarding affordability of prescription 
medications.[22] These conversations may help identify patients who are in need of financial 
assistance for medical and prescription drug costs. Alternatively, knowledge that patients lack 
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convenient transportation to a pharmacy[23, 24] could inform decisions about prescribing oral versus 
intravenous antiemetics.  
To our knowledge, no studies to date have specifically assessed patients’ preferences for IV 
compared to oral antiemetic regimens.[14] However, results from a handful of studies suggest that 
efforts to facilitate the prescription of IV antiemetics may address patients’ perceived barriers to 
achieving adequate prevention of CINV. Specifically, a survey of patients and providers concerning 
communication about CINV showed that patients were twice as likely as providers to report trying to 
limit the number of medications taken to prevent CINV, suggesting that patients may prefer simpler 
regimens.[33] Moreover, in a discrete choice experiment assessing patients’ willingness to pay to 
prevent CINV, the authors concluded that cost contributed more to patients’ choices about avoiding 
CINV than any other single attribute This suggests that the cost of medications to prevent CINV may 
affect patients’ likelihood of using them.[34] The prescription of IV antiemetics, including single-dose 
fosparepitant, would appear to be consistent with available evidence on patients’ preferences 
surrounding antiemetic formulations. In addition to simplifying regimens and minimizing scheduled 
medication administration at home, IV antiemetics are typically covered under Medicare Part B 
(versus Part D); thus, they may be more affordable for the large majority of Medicare beneficiaries 
who have supplemental insurance coverage to assist with their out-of-pocket Part B costs.[13]  
 Our study has a number of limitations. First, we were unable to account for site-level variation 
in care; neither could we separate physicians’ failure to prescribe aprepitant from patients not filling 
prescription. Second, we focused on fee-for-service Medicare beneficiaries with Part D coverage. It is 
unknown whether our findings generalize to younger women, Medicare beneficiaries enrolled in 
Medicare Advantage plans, or women without prescription drug coverage through Part D. Third, only 
111 black women met our study inclusion criteria, which might have resulted in our lacking statistical 
power for some comparisons, particularly in the formulation-specific models. Finally, our data allowed 
us to examine NK1 use through 2011, only one year after the introduction and FDA approval of 
single-dose fosaprepitant. Studies using more current data would be needed to examine longer-term 
effects on overall NK1 use and, ultimately, improvements in CIV prophylaxis.  
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 Our findings demonstrate that NK1 use has improved over time for black and white patients 
following the introduction of IV fosaprepitant and the potentially more convenient and affordable 
alternative to oral aprepitant. This trend is encouraging and suggests that, over time, more patients 
are receiving adequate prevention of CINV in accordance with clinical practice guidelines. However, 
substantial racial gaps in NK1 use remain, indicating that the CINV prevention needs of many black 
women are not being met. Given patients’ preferences for simpler and less expensive antiemetic 
regimens, strategies that facilitate providers’ prescription of IV antiemetics, including fosaprepitant as 
a substitute for three-day oral aprepitant, may improve overall rates of guideline-concordant CINV 
prophylaxis, particularly for patients who have difficulty accessing or adhering to more complex oral 
regimens.  
 
Table 8. Aim 3 Sample Characteristics, by Race 
 White Black p-value 
Number of Patients 976 111  
Characteristics (%)    
Age at Cancer Diagnosis     
 65-66 20.5 25.3 0.80 
 67-68 24.7 24.3  
 69-71 25.3 22.5  
 72-91 29.5 28.8  
Year of Chemotherapy Initiation    
 2007 30.0 32.4 0.90 
 2008 20.9 21.6  
 2009 17.7 18.9  
 2010 15.3 11.7  
 2011 16.0 15.3  
Charlson Comorbidity Score    
 0 78.6 76.6 0.20 
 1 17.1 --  
 >1 4.3 --  
Cancer Stage     
 Stage I 13.1 10.8 0.80 
 Stage II 53.4 55.9  
 Stage III 33.5 33.3  
Hormone Receptor Status     
 HR positive  66.9 63.1 0.60 
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 HR negative  28.6 --  
 Unknown  4.5 --  
Tumor Grade    0.09 
 Low 10.5 --  
 Intermediate 40.4 33.3  
 High 45.7 56.8  
 Unknown  3.5 --  
Lymph Node Involvement     
 Yes  71.1 66.7 0.62 
 No  27.6 --  
 Unknown  1.3 --  
Overall NK1 Use     
Any NK1, % Yes  37.2 27.0 0.03 
Aprepitant, % Yes  27.3 16.2 0.01 
Fosaprepitant, % Yes  13.2 10.9 0.47 
Cells including percentages reflecting Ns<11 or information that would allow Ns<11 to be derived were suppressed to protect 
patients’ identities.  
Patients with “unknown” values for hormone receptor status, tumor grade, and lymph node involvement not included in p-value 
calculations. 
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Table 9. Adjusted NK1 Use Over Time, Overall and by Formulation, Among Black and White Patients 
 White   Black  
Any NK1 Use Risk aRR 95% CI  Risk aRR 95% CI 
 2007 0.24 REF REF  0.13 REF REF 
 2008 (Initial FDA 
Approval)  
0.30 1.25 0.94-1.65  0.12 0.96 0.31-2.99 
 2009  0.41 1.70 1.31-2.21  0.20 1.57 0.58-4.22 
 2010 (Single Dose 
Introduced) 
0.41 1.73 1.32-2.25  0.24 1.95 0.66-5.73 
 2011 0.64 2.67 2.13-3.35  0.32 2.54 1.03-6.25 
Aprepitant Use        
 2007 0.20 REF REF  0.14 REF REF 
 2008 0.25 1.23 0.93-1.63  0.08 0.64 0.18-2.35 
 2009  0.26 1.29 0.96-1.73  0.12 0.91 0.30-2.79 
 2010 0.28 1.36 1.01-1.82  0.05 0.40 0.05-3.09 
 2011 0.21 1.05 0.76-1.46  0.14 1.00 0.32-3.14 
Fosaprepitant Use        
 2009  0.17 REF REF  0.09 REF REF 
 2010 0.20 1.14 0.73-1.80  0.29 3.03 0.67-13.90 
 2011 0.44 2.53 1.75-3.65  0.31 3.26 0.67-15.91 
Throughout the study period, 363 white women and 30 black women used any NK1; 266 white women and 18 black women 
used aprepitant; 129 white women and 12 black women used fosaprepitant.  
Any NK1 and aprepitant models controlled for age, comorbidity, and cancer stage. Fosaprepitant models controlled only for 
age due to insufficient cell sizes.  
Estimates in bold are statistically significant at the p<0.05 level.  
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Differences are not statistically significant at the p<0.05-level. 
 
Figure 3. Racial variation in NK1 use over time.  
 
 
  
 
  
0%	
10%	
20%	
30%	
40%	
50%	
60%	
70%	
2007	 2008	 2009	 2010	 2011	
Adjusted	Risk	NK1	
Use,	White	
Adjusted	Risk	NK1	
Use,	Black	
79 
REFERENCES 
1. Hickok JT, Roscoe JA, Morrow GR, et al. Nausea and emesis remain significant problems of 
chemotherapy despite prophylaxis with 5-hydroxytryptamine-3 antiemetics: A University of 
Rochester James P. Wilmot Cancer Center Community Clinical Oncology Program Study of 
360 cancer patients treated in the community. Cancer 2003;97(11):2880–6. 
2. Cohen L, de Moor CA, Eisenberg P, et al. Chemotherapy-induced nausea and vomiting: 
Incidence and impact on patient quality of life at community oncology settings. Support Care 
Cancer 2007;15(5):497–503. 
3. Bloechl-Daum B, Deuson RR, Mavros P, et al. Delayed nausea and vomiting continue to 
reduce patients' quality of life after highly and moderately emetogenic chemotherapy despite 
antiemetic treatment. J Clin Oncol 2006;24(27):4472–8. 
4. Glaus A, Knipping C, Morant R, et al. Chemotherapy-induced nausea and vomiting in routine 
practice: A European perspective. Support Care Cancer 2004;12(10):708–15. 
5. National Cancer Institute. Nausea and Vomiting. 
http://www.cancer.gov/cancertopics/pdq/supportivecare/nausea/HealthProfessional. 
Accessed February 15, 2016.  
6. Basch E, Prestrud AA, Hesketh PJ, et al. Antiemetics: American Society of Clinical Oncology 
clinical practice guideline update. J Clin Oncol 2011;29(31):4189–98. 
7. Roila F, Herrstedt J, Aapro M, et al. Guideline update for MASCC and ESMO in the 
prevention of chemotherapy- and radiotherapy-induced nausea and vomiting: Results of the 
Perugia consensus conference. Ann Oncol 2010;21 Suppl 5:v232–43. 
8. National Comprehensive Cancer Network (NCCN) Clinical Practice Guidelines in Oncology, 
Anti-emesis. Version 1.2012. [Internet] http://www.medicine.wisc.edu/~williams/anti-
emesis.pdf. Accessed February 15, 2016.  
9. Hesketh PJ. Penny wise, dollar foolish approach to antiemetic use may compromise patient 
care. J Oncol Pract 2009;5(5):221–2. 
10. Center for Medicare and Medicaid Services. Medicare Plan Finder. 
https://http://www.medicare.gov/find-a-plan/questions/home.aspx. Accessed February 15, 
2016.  
11. Check DK, Reeder-Hayes KE, Basch EM, et al. Investigating racial disparities in use of NK1 
receptor antagonists to prevent chemotherapy-induced nausea and vomiting among women 
with breast cancer. Breast Cancer Res Treat 2016; 156(2):351-9.  
12. Grunberg SM CD, Maru A, et al: Phase III randomized double-blind study of single-dose 
fosaprepitant for prevention of cisplatin-induced nausea and vomiting. J Clin Oncol 28:641s, 
2010 (suppl; abstr 9021). 
13. Kaiser Family Foundation. Medicare at a Glance. http://kff.org/medicare/fact-sheet/medicare-
at-a-glance-fact-sheet. Accessed Febuary 15, 2016.  
14. Celio L, Ricchini F, De Braud F. Safety, efficacy, and patient acceptability of single-dose 
fosaprepitant regimen for the prevention of chemotherapy-induced nausea and vomiting. 
Patient Prefer Adherence 2013;7:391–400. 
80 
15. Warren JL, Klabunde CN, Schrag D, et al. Overview of the SEER-Medicare data: Content, 
research applications, and generalizability to the United States elderly population. Med Care 
2002;40(8 Suppl):IV-3–18. 
16. Kris MG, Hesketh PJ, et al. American Society of Clinical Oncology guideline for antiemetics in 
oncology: update 2006. J Clin Oncol 2006;24(18):2932–47. 
17. Roila F, Hesketh PJ, Herrstedt J, et al. Prevention of chemotherapy- and radiotherapy-
induced emesis: Results of the 2004 Perugia International Antiemetic Consensus 
Conference. Ann Oncol 2006;17(1):20–8. 
18. Zou G. A modified poisson regression approach to prospective studies with binary data. Am J 
Epidemiol 2004;159(7):702–6. 
19. McGuire TG, Alegria M, Cook BL, et al. Implementing the Institute of Medicine definition of 
disparities: An application to mental health care. Health Serv Res 2006;41(5):1979–2005. 
20. Sin DD, Svenson LW, Man SF. Do area-based markers of poverty accurately measure 
personal poverty? Can J Public Health 2001;92(3):184–7. 
21. Diez-Roux AV, Kiefe CI, Jacobs DR, Jr., et al. Area characteristics and individual-level 
socioeconomic position indicators in three population-based epidemiologic studies. Ann 
Epidemiol 2001;11(6):395–405. 
22. Cobaugh DJ, Angner E, Kiefe CI, et al. Effect of racial differences on ability to afford 
prescription medications. Am J Health Syst Pharm 2008;65(22):2137–43. 
23. Probst JC, Laditka SB, Wang JY, et al. Effects of residence and race on burden of travel for 
care: cross sectional analysis of the 2001 US National Household Travel Survey. BMC Health 
Serv Res 2007;7:40. 
24. Kullgren JT, McLaughlin CG, Mitra N, et al. Nonfinancial barriers and access to care for U.S. 
adults. Health Serv Res 2012;47(1 Pt 2):462–85. 
25. Jha AK, Orav EJ, Epstein AM. Low-quality, high-cost hospitals, mainly in South, care for 
sharply higher shares of elderly black, Hispanic, and medicaid patients. Health Aff (Millwood) 
2011;30(10):1904–11. 
26. Samuel CA, Landrum MB, McNeil BJ, et al. Racial disparities in cancer care in the Veterans 
Affairs health care system and the role of site of care. Am J Public Health 2014;104 Suppl 
4:S562–71. 
27. Kaiser R. Antiemetic guidelines: Are they being used? Lancet Oncol 2005;6(8):622–5. 
28. Piette JD, Wagner TH, Potter MB, et al. Health insurance status, cost-related medication 
underuse, and outcomes among diabetes patients in three systems of care. Med Care 
2004;42(2):102–9. 
29. Nolte MJ, Berkery R, Pizzo B, et al. Assuring the optimal use of serotonin antagonist 
antiemetics: The process for development and implementation of institutional antiemetic 
guidelines at Memorial Sloan-Kettering Cancer Center. J Clin Oncol 1998;16(2):771–8. 
30. Dranitsaris G, Leung P, Warr D. Implementing evidence based antiemetic guidelines in the 
oncology setting: Results of a 4-month prospective intervention study. Support Care Cancer 
2001;9(8):611–8. 
81 
31. Mertens WC, Higby DJ, Brown D, et al. Improving the care of patients with regard to 
chemotherapy-induced nausea and emesis: The effect of feedback to clinicians on 
adherence to antiemetic prescribing guidelines. J Clin Oncol 2003;21(7):1373–8. 
32. Zeber JE, Miller AL, Copeland LA, et al. Medication adherence, ethnicity, and the influence of 
multiple psychosocial and financial barriers. Adm Policy Ment Health 2011;38(2):86–95. 
33. Salsman JM, Grunberg SM, Beaumont JL, et al. Communicating about chemotherapy-
induced nausea and vomiting: A comparison of patient and provider perspectives. J Natl 
Compr Canc Netw 2012;10(2):149–57. 
34. Miller PJ, Balu S, Buchner D, et al. Willingness to pay to prevent chemotherapy induced 
nausea and vomiting among patients with breast, lung, or colorectal cancer. J Med Econ 
2013;16(10):1179–89. 
 
82 
CHAPTER 7. DISCUSSION  
Conclusions 
Race and NK1 Use  
 Findings from this study provide evidence about the quality of CINV prophylaxis among black 
and white breast cancer patients beginning highly emetogenic adjuvant chemotherapy. We observed 
substantial racial disparities in guideline-recommended use of NK1s for CINV prophylaxis: Black 
women were 32% less likely than white women to use any NK1 and 46% less likely to use oral 
aprepitant specifically. We offer two main hypotheses as to why aprepitant may be underused by 
black women.  
 First, black women may be equally as likely as white women to be prescribed aprepitant but 
less likely to fill their prescriptions, possibly due to financial or other access barriers.[22] Second, 
black women may be more likely to see providers who do not prescribe NK1s in accordance with 
clinical guidelines because they are more likely to be treated in lower-performing settings.[25, 26] 
Both explanations seem plausible given our findings. Specifically, the fact that disparities in NK1 and 
aprepitant use were somewhat attenuated when socioeconomic status (SES)-related factors were 
added to the models suggests that the disparities are at least partly explained by SES differences 
between black and white women. These SES differences could translate into differential ability to pay 
for prescription drugs or differential access to high-quality care (including guideline-adherent 
antiemetic prescribing). Our identification of racial disparities in oral but not intravenous NK1 use 
supports the hypothesis that fosaprepitant is more affordable for and more easily accessed by 
patients.  
Racial Variation in Post-Chemotherapy Healthcare Utilization for CINV  
 We found that black women were less likely to receive CINV-related care in the post-
chemotherapy period. This finding was counter to our hypothesis that black women would be more 
likely to experience CINV-related utilization because of evidence of their underuse of NK1s for CINV 
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prophylaxis. Instead, in this SEER-Medicare sample, black women were at lower risk for both using 
an NK1 and for receiving treatment for CINV. Although the racial difference in CINV-related utilization 
was not statistically significant after adjustment for covariates, estimates were still consistent with 
lower utilization among black patients. We observed no racial variation in the use of any outpatient 
services during the 14 days following chemotherapy initiation. Thus, it seems unlikely that racial 
differences in general access or care-seeking behavior fully explain racial variation in CINV-related 
services use.  
 It may be that the variation we observed is specific to CINV or symptom management. There 
are two reasons black women may be less likely to have claims with diagnosis codes related to CINV. 
First, black and white women may be at equal risk of experiencing CINV but black women may be 
less likely to report this experience to their providers.[35] A second potential explanation is that the 
black women in our sample may differ from white women with respect to unmeasured factors (e.g., 
body mass index), which could affect the incidence of treatment-induced side effects like CINV.[36–
38] Reporting bias could also occur at the provider level. Our measures of healthcare utilization rely 
on providers’ coding of diagnoses. If providers are less likely to code nausea and related conditions 
among black patients, for example, due to competing or more pressing health concerns, rates of 
CINV could appear artificially low in black patients.  
The positive association between prophylactic NK1 use and CINV-related utilization was also 
surprising. We suspect confounding—specifically confounding by indication—may account for this 
relationship. For example, patients’ (or their providers’) level of concern about CINV might help 
explain why patients who receive NK1s are also more likely to subsequently receive care related to 
the side effect. Our data suggest that white patients may be more likely to both use NK1s to prevent 
CINV and be treated for CINV, raising the question of whether black women are not being identified 
as being in need of CINV prevention and treatment. It is also possible that black women are 
concentrated within providers or systems where it may be more difficult to access high-quality cancer 
care,[25] including medications to prevent side effects and services to address them. Black women 
may also experience access barriers that make both obtaining NK1s and side effect–related care 
more difficult.  
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Changes in NK1 Use and Disparities over Time  
In our sample, fosaprepitant use increased substantially for both black and white patients 
between its initial approval in 2008 and the end of our study period in 2011. This increase suggests 
that, particularly after single-dose fosaprepitant was introduced in 2010 as an alternative to three-day 
aprepitant, providers recognized the IV drug as a more convenient option for all patients. That NK1 
use has improved for all patients in our sample is encouraging and suggests that over time more 
patients are receiving adequate prevention of CINV. However, the persistent racial gap that we 
observed indicates that the CINV prevention needs of many black women are not being met. Thus, 
targeted efforts to increase NK1 use among black patients may be needed. 
To inform these efforts, future research should assess the contribution of provider versus 
patient-level barriers to use. For example, black women may be more likely to receive care within 
lower-performing systems[25] where providers do not routinely prescribe NK1s in accordance with 
clinical guidelines either because the systems’ antiemetic order sets do not align with guidelines or 
individual prescribers are unfamiliar with the guidelines.[27] Previous research has demonstrated that 
several institution-wide strategies, including development of institutional guidelines[29–31] and 
implementation of guidelines through use of physician audit and feedback,[30, 31] opinion leaders, 
and preprinted antiemetic orders[31] may be effective strategies for improving providers’ antiemetic 
prescribing.  
Alternatively, if black and white patients are equally likely to be prescribed an NK1 but black 
patients are less likely to fill aprepitant prescriptions, patient-level barriers are likely to contribute to 
persistent disparities in NK1 use. In particular, disparities in use may be partly explained by patients’ 
differential ability to afford aprepitant[22, 32] or differential access to a pharmacy, for example, due to 
lack of convenient transportation.[23, 24] Interventions to address patient-level barriers to aprepitant 
use might encourage conversations between oncologists and patients regarding access to and 
affordability of prescription medications.[22] These conversations may help identify patients who are 
in need of financial assistance for medical and prescription drug costs. Providers’ knowledge of 
patients’ difficulty with pharmacy access or medication costs could also inform decisions about 
prescribing oral versus intravenous antiemetics for all patients.  
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Clinical and Policy Implications 
 We observed persistent racial disparities in use of NK1s to prevent CINV among Medicare 
beneficiaries initiating highly emetogenic chemotherapy for early-stage breast cancer. Although, in 
our sample, disparities in NK1 use did not appear to contribute to disparities in women’s CINV-related 
services use as captured by Medicare administrative claims, disparities in CINV prophylaxis are 
nonetheless concerning if they contribute to disparities in quality of life (QOL) or women’s adherence 
to chemotherapy schedules. Future research should assess the contribution of disparities in quality of 
side effect management to disparities in the latter two outcomes. In addition, before developing 
interventions to address disparities in quality of CINV prophylaxis, future studies should seek to 
elucidate the underlying causes of disparities. Namely, keys to better understanding the source of 
disparities will lie in examining the relative roles of patient-level factors (i.e., financial and other 
access barriers) and provider-level factors (i.e., variable prescribing at the provider or practice level). 
To the extent that patient-level factors explain disparities in CINV prophylaxis, the results of our study 
together with prior research exploring patients’ perspectives on antiemetic use[33, 34] suggest that 
policies and strategies that facilitate providers’ prescription of IV antiemetics, including fosaprepitant 
as a substitute for three-day oral aprepitant, may improve overall rates of guideline-concordant CINV 
prophylaxis. This may be particularly true for patients who have difficulty accessing or adhering to 
more complex oral regimens,[9] including racial minority and low-income patients.  
Limitations 
 This section addresses limitations of the current study, and offers recommendations for future 
studies that address these shortcomings. One limitation of our study concerns the generalizability of 
our findings. We focused on fee-for-service Medicare beneficiaries with Medicare Part D coverage. It 
is unknown whether our findings generalize to younger women with early-stage breast cancer, 
Medicare beneficiaries enrolled in an HMO, or women without prescription drug coverage through 
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Part D. Additionally, because of the limited number of minority women represented in SEER, we may 
have lacked statistical power for some comparisons. This is particularly true of the fosaprepitant 
models, which were limited to women who initiated chemotherapy in 2009 or later. Future studies 
could attempt to replicate our findings in samples of breast cancer patients who are more diverse with 
respect to race and ethnicity, age, and insurance status.  
Additional limitations relate to the use of Medicare administrative claims data. First, we could 
not separate physicians’ failure to prescribe aprepitant from patients not filling prescriptions. Thus, 
although we have documented the existence of disparities, we are unable to identify the underlying 
causes of the observed disparities using SEER-Medicare data. Future studies should attempt to use 
clinical data to ascertain whether the disparities identified here reflect disparities in aprepitant 
prescriptions or fills. If black and white women are equally likely to be prescribed NK1s but black 
women are less likely to fill these prescriptions, disparities may in fact reflect barriers related to 
affordability and accessibility. If black women are less likely to be prescribed aprepitant, disparities 
may reflect provider-level factors. Namely, black women may be more likely to see providers who do 
not prescribe NK1s in accordance with clinical practice guidelines or providers may be less likely to 
prescribe aprepitant to patients who are minorities or low-income due to perceptions about patients’ 
likelihood of filling prescriptions or complying with the dosing regimen. Second, we may have under-
captured NK1 use overall, particularly in situations where the oral medication was provided in clinic 
and not billed to Medicare. However, we do not believe that capture issues would differentially affect 
black versus white patients, so comparisons between groups should be valid nonetheless.  
Third, our use of claims data prevented our ability to measure several clinically meaningful 
outcomes in Aim 2. In addition to assessing women’s post-chemotherapy healthcare utilization, 
including their use of services related to CINV, we would have ideally also assessed their early 
termination of or withdrawal from chemotherapy as well as extended gaps between chemotherapy 
cycles. Using SEER-Medicare, we were unable to reliably determine a woman’s intended 
chemotherapy regimen or duration, making it infeasible to recognize unintended interruptions or 
termination of treatment that could potentially occur due to uncontrolled side effects. Studies using 
clinical data may be able to more accurately define a woman’s intended treatment regimen and 
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deviations from it. Because adherence to the chemotherapy schedule is an important determinant of 
its effectiveness, it is a very important outcome for future research on breast cancer disparities and 
consequences of uncontrolled side effects.  
Future Directions  
Understanding how treatment-induced side effect management influences racial disparities in 
care and outcomes for patients with breast and other cancers will be imperative for informing 
interventions that target modifiable factors to reduce disparities. The results of this dissertation 
provide a foundation for future research that: 
1. Uses clinical data to assess the relationship between breast cancer patients’ NK1 use 
and their likelihood of experiencing delays in or early termination of adjuvant 
chemotherapy;  
2. Explores patients’ perceptions about potential barriers to taking oral antiemetics 
(including aprepitant) for the prevention of CINV and their preferences for oral versus 
intravenous drugs;  
3. Explores providers’ perceptions about potential barriers to guideline-adherent antiemetic 
prescribing and use;  
4. Assesses disparities in the prophylactic use of other supportive cancer therapies (e.g., 
growth factors) and the impact on disparities in chemotherapy use and outcomes; and  
5. Informs interventions to maximize appropriate use of supportive cancer therapies, 
including antiemetics to prevent CINV. 
In addition, several specific research studies would directly extend the results of this 
dissertation by helping elucidate the sources of disparities in NK1 use. For example, natural 
extensions of this study could use data on patients with diverse cancers within a health system or 
group of health systems to: (1) assess variation in patients’ receipt of prescriptions for aprepitant 
versus disparities in their filling of aprepitant prescriptions; (2) if variation exists at the prescriber level, 
assess the effects of provider or practice characteristics on under-prescription; (3) if variation exists at 
the patient level (i.e., prescription fills), assess the role of individual-level measures of SES on under-
filling. Moreover, access to more recent data (i.e., 2011–2016) would allow for an updated 
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assessment of the effect of antiemetic formulation changes on use of the drugs and the current extent 
of disparities in use to inform the scope of the problem and potential interventions to increase 
guideline-concordant antiemetic prescribing and use, particularly for low-access groups.  
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